# Title

 Food and Drugs. PART 201—LABELING


# ID

 CFR-2018-title21-vol4.Pt. 201


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(1.0, 'GBP'), (0.75, 'GBP'), (25000.0, 'USD'), (4.0, 'GBP')]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Constraints | ['no later than', 'after', 'prior to', 'equal to', 'minimum of', 'less than or equal to', 'greater than', 'within', 'maximum of', 'highest', 'more than', 'first of', 'before', 'minimum', 'less than', 'later than', 'no more than', 'not to exceed', 'greater', 'at least', 'maximum', 'exceed']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Duration    | ['4.0 hour', '80.0 minute', '3.0 year', '2.0 year', '12.0 year', '90.0 day', '270.0 day', '1.0 year', '12.0 month', '65.0 year', '16.0 year', '30.0 second', '1 second', '40.0 minute', '30.0 day', '2.0 day', '1 quarter', '45.0 minute', '30 second', '11.0 year', '15.0 minute', '60.0 minute', '10.0 day', '2.0 hour', '20.0 minute', '60.0 day', '5.0 year', '9.0 year', '6.0 month', '24.0 hour']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Condition   | ['subject to', 'until', 'if not', 'as soon as', 'where', 'provided that', 'when', 'not subject to', 'unless', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Entities    | ['Pediatric', 'Switzerland', 'Data', 'Remain', 'Portable', 'Hyphens', 'Explain', 'Paragraph', 'Note', 'English', 'Adequate', 'Rockville, MD', 'United States', 'Isoproterenol', 'United States Pharmacopeia', 'Bar', 'D, and K', 'Exemption', 'Use', 'Paragraphs', 'G112', 'Severe', 'New', 'Daily', 'Numerous', 'Obtain', 'Adverse', 'Aluminum', 'Spanish', 'Pharmacokinetic', 'Food', 'Dependence', 'Children', 'Cardiac', 'Erythemal', 'Excess', 'Asthma', 'Specific Populations', 'Information', 'Technology', 'Sulfite', 'Test', 'Pediatrics', 'Indications', 'Calcium', 'Dilute', 'Research', 'Reverse', 'Mean', 'U.S. Pharmacopeia', 'Allergy', 'Certain', 'Select', 'Specific', 'Request', 'Phenylalanine', 'Woods', 'Appropriate', 'Detailed', 'Drug', 'Allergic', 'Significant', 'Dosage', 'Accidental', 'Beltsville, MD', 'Highlights', 'Add', 'Magnesium', 'Uses', 'U.S', 'Wait', 'Expose', 'Human', 'Incorporated', 'Principal', 'Pharmacologic', 'Medical', 'Sunblock', 'Reject', 'Drugs', 'Additional', 'Tannic', 'Ipecac', 'London, England', 'Reminder', 'Granular', 'Epinephrine', 'Sodium', 'Geriatric', 'Estradiol', 'Esophageal', 'Phenindione', 'Less', 'Such', 'Active', 'Cool', 'Determine', 'Animal', 'Safety', 'Contains', 'Sore', 'Notice', 'Avoid', 'Format', 'Substance', 'Radiation', 'Periodic', 'Dissolve', 'Puerto Rico', 'Contraindications', 'Health', 'Infertility', 'Reye', 'Rm', 'Warnings', 'Potassium', 'Inquiry', 'Sciences', 'Acetophenetidin'] |
| Date        | ['2005-09-24', '2005-06-30', '2005-04-18', '1999-12-15', '2006-06-30', '2018-03-04', '2010-06-30', '2005-11-29', '2002-06-30', '1967-06-01', '1964-04-23', '1961-11-25', '2005-06-29', '2004-04-23', '1994-02-28', '2009-06-30', '2018-01-04', '2012-06-30', '2007-06-30', '1969-07-01', '1932-08-01', '2000-11-15', '2018-11-02', '2018-12-01', '1998-06-22', '1997-04-22', '1972-05-15', '2018-11-04', '2003-06-29', '2018-01-02', '2004-06-30', '2001-06-30', '1963-12-01', '2004-10-18', '1941-12-04', '2013-06-30', '2008-06-19', '2003-06-30', '2002-06-29', '2004-07-26', '2018-09-24', '2011-06-30', '1998-09-18', '2010-04-29', '2004-06-29', '2004-04-19']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |


# Structured Analysis With Context

 


## Money

| Money            | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4.0, 'GBP')     | (i) On packages containing less than 4 pounds or 1 gallon and labeled in terms of weight or fluid measure:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                  |               (1) The declaration shall be expressed both in ounces, with identification by weight or by liquid measure and, if applicable (1 pound or 1 pint or more) followed in parentheses by a declaration in pounds for weight units, with any remainder in terms of ounces or common or decimal fractions of the pound (see examples set forth in paragraphs (k) (1) and (2) of this section), or in the case of liquid measure, in the largest whole units (quarts, quarts and pints, or pints, as appropriate) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart (see examples set forth in paragraphs (k) (3) and (4) of this section). |
| (1.0, 'GBP')     | (i) On packages containing less than 4 pounds or 1 gallon and labeled in terms of weight or fluid measure:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                  |               (1) The declaration shall be expressed both in ounces, with identification by weight or by liquid measure and, if applicable (1 pound or 1 pint or more) followed in parentheses by a declaration in pounds for weight units, with any remainder in terms of ounces or common or decimal fractions of the pound (see examples set forth in paragraphs (k) (1) and (2) of this section), or in the case of liquid measure, in the largest whole units (quarts, quarts and pints, or pints, as appropriate) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart (see examples set forth in paragraphs (k) (3) and (4) of this section). |
| (4.0, 'GBP')     | (j) On packages containing 4 pounds or 1 gallon or more and labeled in terms of weight or fluid measure, the declaration shall be expressed in pounds for weight units with any remainder in terms of ounces or common or decimal fractions of the pound; in the case of fluid measure, it shall be expressed in the largest whole unit (gallons, followed by common or decimal fractions of a gallon or by the next smaller whole unit or units (quarts or quarts and pints)) with any remainder in terms of fluid ounces or common or decimal fractions of the pint or quart; see paragraph (k)(5) of this section.                                                                           |
| (0.75, 'GBP')    | (2) A declaration of three-fourths pound avoirdupois weight shall be expressed as &#8220;Net wt.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (25000.0, 'USD') | (ii) Compliance by April 19, 2004, for OTC antidiarrheal and overindulgence drug products that contain bismuth subsalicylate as an active ingredient and have annual sales greater than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (25000.0, 'USD') | (iii) Compliance by April 18, 2005, for OTC antidiarrheal and overindulgence drug products that contain bismuth subsalicylate as an active ingredient and have annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |


## Constraints

| Constraints           | Context                                                                                                                                                                         |
|:----------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| more than             | except as follows: (1) If the person performs more than one half of the applicable operations listed in                                                                         |
| at least              | other firms.&#8221;; or (2) If the person performs at least one applicable operation listed in paragraph (b) of                                                                 |
| at least              | other firms.&#8221;; or (2) If the person performs at least one applicable operation listed in paragraph (b) of                                                                 |
| after                 | apply to consumer commodity labels developed or revised after  July 1, 1969.                                                                                                    |
| greater than          | a manner that creates an impression of value greater than  their true functional role in the formulation.                                                                       |
| at least              | running text, the established name shall be used at least once in the running text in association with                                                                          |
| at least              | running text, the established name shall be used at least once in the running text in association with                                                                          |
| at least              | running text, the established name shall be used at least once in the running text in association with                                                                          |
| at least              | the column, the established name shall be used at least once in such column of running text in                                                                                  |
| at least              | the column, the established name shall be used at least once in such column of running text in                                                                                  |
| at least              | the column, the established name shall be used at least once in such column of running text in                                                                                  |
| at least              | name shall be printed in letters that are at least half as large as the letters comprising the                                                                                  |
| greater               | the use of label space to give materially greater conspicuousness to any other word, statement, or information,                                                                 |
| greater               | (2) The use of label space to give  greater conspicuousness to any word, statement, or other information                                                                        |
| minimum               | Food, Drug, and Cosmetic Act requires, at a minimum , that the label bear the statement &#8220;Rx                                                                               |
| more than             | chapter) define an infant as a child not more than  12 months old.                                                                                                              |
| more than             | it refers to a child who is not more than  1 year of age, or a child not                                                                                                        |
| more than             | it refers to a child who is not more than  1 year of age, or a child not                                                                                                        |
| after                 | by order, in the form of a letter, after notifying the manufacturer of its intent to require                                                                                    |
| after                 | by order, in the form of a letter, after notifying the manufacturer of its intent to require                                                                                    |
| within                | formulation described in paragraph (a) of this section within a time specified in the order, if FDA                                                                             |
| within                | formulation described in paragraph (a) of this section within the time specified by FDA, the drug product                                                                       |
| minimum               | have a bar code that contains, at a minimum , the appropriate National Drug Code (NDC) number                                                                                   |
| more than             | decimal fraction shall not be carried out to more than three places, except in the case of a                                                                                    |
| minimum               | the declaration shall be considered to express the minimum quantity and the variation above the stated measure                                                                  |
| exceed                | and the contents of the package do not exceed  8 grams.                                                                                                                         |
| within                | Since the dosage for some prescription drugs varies  within extremely wide limits, depending upon the conditions being                                                          |
| after                 | or efficacy supplement is submitted anytime on or after  June 30, 2006.                                                                                                         |
| after                 | efficacy supplement is submitted for approval on or after June 30, 2006, proposed conforming labeling must be                                                                   |
| no later than         | supplement with proposed conforming labeling must be submitted no later than  June 30, 2009.                                                                                    |
| no later than         | supplement with proposed conforming labeling must be submitted no later than  June 30, 2010.                                                                                    |
| no later than         | supplement with proposed conforming labeling must be submitted no later than  June 30, 2011.                                                                                    |
| no later than         | supplement with proposed conforming labeling must be submitted no later than  June 30, 2012.                                                                                    |
| no later than         | supplement with proposed conforming labeling must be submitted no later than  June 30, 2013.                                                                                    |
| within                | is considered &#8220;appropriate pediatric contraindications, warnings, or precautions&#8221; within the meaning of section 505A(l)(2) of the Federal                           |
| after                 | the labeling, identified as such, placed prominently immediately after  the last section of the labeling.                                                                       |
| no later than         | accompany the prescription drug labeling must be implemented no later than  June 30, 2007.                                                                                      |
| no later than         | the prescription drug labeling, which must be implemented no later than  June 30, 2007.                                                                                         |
| not to exceed         | warning required by paragraph (c)(1) of this section, not to exceed  a length of 20 lines.                                                                                      |
| within                | The heading and the summary must be contained  within  a box and bolded.                                                                                                        |
| at least              | be listed under this heading in Highlights for at least 1 year after the date of the labeling                                                                                   |
| after                 | heading in Highlights for at least 1 year after the date of the labeling change and must                                                                                        |
| within                | If additional subheadings are used  within a labeling section, they must be preceded by                                                                                         |
| before                | there are specific conditions that should be met before the drug is used on a long term                                                                                         |
| prior to              | be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.&#8221;) (4) 3                                   |
| after                 | used, a statement of the strength in parentheses after the metric designation; and (ii) A description of                                                                        |
| before                | recommended frequency with which tests should be performed before , during, and after therapy.                                                                                  |
| after                 | which tests should be performed before, during, and after  therapy.                                                                                                             |
| within                | or by a combination of these, as appropriate. within                                                                                                                            |
| within                | must be listed in decreasing order of frequency. within                                                                                                                         |
| within                | overall safety database), adverse reactions must be grouped within specified frequency ranges as appropriate to the safety                                                      |
| less than             | (e.g., adverse reactions occurring at a rate of less than  1/100, adverse reactions occurring at a rate of                                                                      |
| less than             | (e.g., adverse reactions occurring at a rate of less than  1/100, adverse reactions occurring at a rate of                                                                      |
| before                | pregnancy testing and/or contraception are required or recommended before , during, or after drug therapy and/or when                                                           |
| after                 | contraception are required or recommended before, during, or after drug therapy and/or when there are human and/or                                                              |
| greater               | low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function,                                                                 |
| minimum               | Information regarding bioavailability, the effect of food,  minimum concentration (Cmin), maximum concentration (Cmax), time to maximum                                         |
| maximum               | bioavailability, the effect of food, minimum concentration (Cmin), maximum  concentration (Cmax), time to                                                                       |
| maximum               | bioavailability, the effect of food, minimum concentration (Cmin), maximum  concentration (Cmax), time to                                                                       |
| after                 | used, a statement of the strength in parentheses after the metric designation; (ii) The units in which                                                                          |
| minimum of            | and (c) of this section must be a minimum of 8 points, except for labeling information that is                                                                                  |
| within                | except for labeling information that is on or within the package from which the drug is to                                                                                      |
| minimum of            | and (c) of this section must be a minimum of 8 points, except for labeling information that is                                                                                  |
| at least              | and must precede the heading or subheading by at least two square em's (i.e., two squares of the                                                                                |
| within                | Each subheading  within  a section must be indented and not bolded.                                                                                                             |
| more than             | decimal fraction shall not be carried out to more than  two places.                                                                                                             |
| at least              | the principal display panel, shall be separated, by at least a space equal to the height of the                                                                                 |
| equal to              | shall be separated, by at least a space equal to the height of the lettering used in the                                                                                        |
| at least              | the principal display panel, shall be separated, by at least a space equal to the height of the                                                                                 |
| equal to              | shall be separated, by at least a space equal to the height of the lettering used in the                                                                                        |
| within                | shall be placed on the principal display panel within the bottom 30 percent of the area of                                                                                      |
| within                | shall be placed on the principal display panel within the bottom 30 percent of the area of                                                                                      |
| exceed                | height to width of the letter shall not exceed a differential of 3 units to 1 unit,                                                                                             |
| no more than          | differential of 3 units to 1 unit, i.e., no more than  3 times as high as it is wide.                                                                                           |
| minimum               | &#8220;o&#8221; or its equivalent that shall meet the minimum  standards.                                                                                                       |
| minimum               | used, each component numeral shall meet one-half the minimum  height standards.                                                                                                 |
| less than             | complying with the following type specifications: (1) Not less than one-sixteenth inch in height on packages the principal                                                      |
| less than             | (2) Not  less than one-eighth inch in height on packages the principal                                                                                                          |
| more than             | display panel of which has an area of more than  five but not                                                                                                                   |
| more than             | display panel of which has an area of more than  five but not                                                                                                                   |
| less than             | (3) Not  less than three-sixteenths inch in height on packages the principal                                                                                                    |
| more than             | display panel of which has an area of more than  25 but not                                                                                                                     |
| more than             | display panel of which has an area of more than  25 but not                                                                                                                     |
| less than             | (4) Not  less than one-fourth inch in height on packages the principal                                                                                                          |
| more than             | display panel of which has an area of more than 100 square inches, except not less than one-half                                                                                |
| less than             | (4) Not  less than one-fourth inch in height on packages the principal                                                                                                          |
| more than             | display panel of which has an area of more than 100 square inches, except not less than one-half                                                                                |
| less than             | (i) On packages containing  less than 4 pounds or 1 gallon and labeled in                                                                                                       |
| less than             | If the net weight of the package is  less than 1 ounce avoirdupois or the net fluid measure                                                                                     |
| less than             | If the net weight of the package is  less than 1 ounce avoirdupois or the net fluid measure                                                                                     |
| more than             | (2) The declaration may appear in  more than  one line.                                                                                                                         |
| exceed                | and the contents of the package do not exceed  8 grams.                                                                                                                         |
| before                | &#8220;If pregnant or breast-feeding, ask a health professional before use.&#8221; [first four words of this statement in                                                       |
| maximum               | teaspoonful) if the sodium content of a single maximum recommended dose of the product (which may be                                                                            |
| maximum               | the amount of sodium present in the labeled maximum daily dose of the product is more than                                                                                      |
| more than             | labeled maximum daily dose of the product is more than 140 milligrams: &#8220;Ask a doctor before use if                                                                        |
| before                | is more than 140 milligrams: &#8220;Ask a doctor before use if you have [in bold type] [bullet]&#8201;1                                                                         |
| maximum               | if the amount of sodium in the labeled maximum daily dose is 5 milligrams or less and                                                                                           |
| maximum               | if the amount of sodium in the labeled maximum  daily dose is 35 milligrams or less.                                                                                            |
| maximum               | if the amount of sodium in the labeled maximum  daily dose is 140 milligrams or less.                                                                                           |
| after                 | or initially delivered for introduction into interstate commerce after April 22, 1997, is misbranded under sections 201(n)                                                      |
| after                 | or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n)                                                  |
| after                 | subject to drug marketing applications approved on or after  April 23, 2004.                                                                                                    |
| before                | monograph, or subject to drug marketing applications approved before  April 23, 2004.                                                                                           |
| less than             | If  less than  1 gram, milligrams should be used.                                                                                                                               |
| after                 | or initially delivered for introduction into interstate commerce after November 29, 2005, is misbranded under sections 201(n)                                                   |
| more than             | If the drug facts labeling appears on  more than one panel, the title &#8220;Drug Facts (continued)&#8221; shall                                                                |
| more than             | the drug or, where the drug consists of more than one ingredient, the general pharmacological categories or the                                                                 |
| before                | (iv) &#8220;Ask a doctor  before use if you have&#8221; [in bold type] or,                                                                                                      |
| before                | (iv) &#8220;Ask a doctor  before use if you have&#8221; [in bold type] or,                                                                                                      |
| before                | (v) &#8220;Ask a doctor or pharmacist  before use if you are&#8221; [in bold type] or,                                                                                          |
| before                | (v) &#8220;Ask a doctor or pharmacist  before use if you are&#8221; [in bold type] or,                                                                                          |
| minimum               | 1-800-FDA-1088.&#8221; The telephone number must appear in a minimum  6-point bold letter height or type size.                                                                  |
| within                | or approved drug application that do not fit within one of the categories listed in paragraphs (c)(5)(i)                                                                        |
| before                | of a telephone or telephone receiver may appear before  the heading.                                                                                                            |
| minimum               | The telephone number must appear in a  minimum  6-point bold type.                                                                                                              |
| greater               | shall be the larger of either 8-point or greater  type, or 2-point sizes                                                                                                        |
| greater than          | either 8-point or greater type, or 2-point sizes greater than  the point size of the text.                                                                                      |
| at least              | shall be legible and clearly presented, shall have at least 0.5-point leading (i.e., space between two lines of                                                                 |
| no more than          | be any single, clear, easy-to-read type style, with no more than  39 characters per inch.                                                                                       |
| more than             | (4) When there is  more than one statement, each individual statement listed under the                                                                                          |
| at least              | separated from an appropriate heading or subheading by at least two square &#8220;ems&#8221; (i.e., two squares of the                                                          |
| more than             | If  more than one bulleted statement is placed on the same                                                                                                                      |
| at least              | the beginning of the next bulleted statement by at least two square &#8220;ems&#8221; and the complete additional bulleted                                                      |
| more than             | through (c)(9) of this section may appear on more than one panel on the outside container of the                                                                                |
| more than             | If the OTC drug product contains  more than one active ingredient, the active ingredients shall be                                                                              |
| more than             | If  more than one active ingredient has the same purpose, the                                                                                                                   |
| after                 | this section appears on a subsequent panel immediately after the &#8220;Drug Facts (continued)&#8221; title, a horizontal hairline                                              |
| within                | A horizontal hairline extending  within two spaces on either side of the &#8220;Drug                                                                                            |
| more than             | to appear on a principle display panel, requires more than 60 percent of the total surface area available                                                                       |
| more than             | In determining whether  more than 60 percent of the total surface area available                                                                                                |
| minimum               | of this section, shall be limited to the minimum required uses reflected in the applicable monograph, as                                                                        |
| greater               | shall be the larger of either 7-point or greater  type, or 1-point size                                                                                                         |
| greater than          | either 7-point or greater type, or 1-point size greater than  the point size of the text.                                                                                       |
| less than             | (d)(3) of this section shall apply except that less than 0.5-point leading may be used, provided the ascenders                                                                  |
| more than             | of this section shall apply except that if more than one bulleted statement is placed on the same                                                                               |
| maximum               | teaspoonful) if the calcium content of a single maximum recommended dose of the product (which may be                                                                           |
| less than             | If the dosage unit contains  less than  1 gram of calcium, milligrams should be used.                                                                                           |
| maximum               | the amount of calcium present in the labeled maximum daily dose of the product is more than                                                                                     |
| more than             | labeled maximum daily dose of the product is more than 3.2 grams: &#8220;Ask a doctor before use if                                                                             |
| before                | is more than 3.2 grams: &#8220;Ask a doctor before use if you have [in bold type] [bullet]&#8201;1                                                                              |
| after                 | or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n)                                                  |
| after                 | subject to drug marketing applications approved on or after  April 23, 2004.                                                                                                    |
| before                | monograph, or subject to drug marketing applications approved before  April 23, 2004.                                                                                           |
| maximum               | teaspoonful) if the magnesium content of a single maximum recommended dose of the product (which may be                                                                         |
| less than             | If the dosage unit contains  less than  1 gram of magnesium, milligrams should be used.                                                                                         |
| maximum               | the amount of magnesium present in the labeled maximum daily dose of the product is more than                                                                                   |
| more than             | labeled maximum daily dose of the product is more than 600 milligrams: &#8220;Ask a doctor before use if                                                                        |
| before                | is more than 600 milligrams: &#8220;Ask a doctor before use if you have [in bold type] [bullet]&#8201;1                                                                         |
| after                 | or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n)                                                  |
| after                 | subject to drug marketing applications approved on or after  April 23, 2004.                                                                                                    |
| before                | monograph, or subject to drug marketing applications approved before  April 23, 2004.                                                                                           |
| maximum               | teaspoonful) if the potassium content of a single maximum recommended dose of the product (which may be                                                                         |
| less than             | If the dosage unit contains  less than  1 gram of potassium, milligrams should be used.                                                                                         |
| maximum               | the amount of potassium present in the labeled maximum daily dose of the product is more than                                                                                   |
| more than             | labeled maximum daily dose of the product is more than 975 milligrams: &#8220;Ask a doctor before use if                                                                        |
| before                | is more than 975 milligrams: &#8220;Ask a doctor before use if you have [in bold type] [bullet]&#8201;1                                                                         |
| after                 | or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n)                                                  |
| after                 | subject to drug marketing applications approved on or after  April 23, 2004.                                                                                                    |
| before                | monograph, or subject to drug marketing applications approved before  April 23, 2004.                                                                                           |
| before                | there are specific conditions that should be met before the drug is used on a long-term basis,                                                                                  |
| greater               | Any statements comparing the safety or effectiveness, either greater or less, of the drug with other agents                                                                     |
| before                | recommended frequency with which tests should be done before , during, and after therapy.                                                                                       |
| after                 | which tests should be done before, during, and after  therapy.                                                                                                                  |
| within                | is available, the categories and the adverse reactions within each category shall be listed in decreasing order                                                                 |
| before                | listed in a category, however, shall be listed before  those reactions, regardless of its frequency.                                                                            |
| within                | is not available, the categories and adverse reactions within each category shall be listed in decreasing order                                                                 |
| less than             | (e.g., one-third of patients; one in 30 patients; less than  one-tenth of patients).                                                                                            |
| greater               | experience, and they do not falsely imply a greater  degree of accuracy than actually exists.                                                                                   |
| prior to              | be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.&#8221; (k) How                                  |
| after                 | statement of the strength is placed in parentheses after the metric designation; (2) The units in which                                                                         |
| within                | bear all such information, but which are packaged within an outer container from which they are removed                                                                         |
| within                | bear all such information, but which are packaged within an outer container from which they are removed                                                                         |
| within                | (c)(1) Labeling on or  within the package from which the drug is to                                                                                                             |
| within                | act, whether or not it is on or within a package from which the drug is to                                                                                                      |
| within                | act, whether or not it is on or within a package from which the drug is to                                                                                                      |
| within                | package of the drug; (c)(1) Labeling on or within the package from which the drug is to                                                                                         |
| within                | act, whether or not it is on or within a package from which the drug is to                                                                                                      |
| within                | appears on the label and labeling on or within the package from which the drug is to                                                                                            |
| after                 | the finished drug product is not further distributed after  it is manufactured until                                                                                            |
| after                 | the finished drug product is not further distributed after  it is manufactured until                                                                                            |
| after                 | limited to prescription dispensing, no exemption shall there after apply to the article unless the dosage form                                                                  |
| after                 | The intended uses of an article may change  after it has been introduced into interstate commerce by                                                                            |
| after                 | The intended uses of an article may change  after it has been introduced into interstate commerce by                                                                            |
| within                | such drug will not be adulterated or misbranded within the meaning of the act upon completion of                                                                                |
| after                 | a copy of such agreement until 2 years after the final shipment or delivery of such drug                                                                                        |
| within                | shipment, delivery, or part is adulterated or misbranded within  the meaning of the act when so removed.                                                                        |
| within                | shipment, delivery, or part is adulterated or misbranded within the meaning of the act when so removed;                                                                         |
| more than             | uniquely intensive in time&#8221; and is applicable to more than  80 percent of the currently marketed drugs.                                                                   |
| after                 | (c) Therefore,  after publication in the Federal Register of a Drug                                                                                                             |
| less than             | material is included therein for claims evaluated as less than &#8220;effective&#8221; or if such claims are included in                                                        |
| within                | provisions of &#167;&#8201;314.70 and &#167;&#8201;514.8 of this chapter within 90 days after publication of the implementation notice                                          |
| after                 | and &#167;&#8201;514.8 of this chapter within 90 days after publication of the implementation notice in the Federal                                                             |
| later than            | into use as soon as possible but not later than the end of the time period allowed for                                                                                          |
| at least              | a claim as other than &#8220;effective&#8221; shall be at least of the same size and color and degree                                                                           |
| at least              | &#167;&#8201;202.1(e)(1) of this chapter and shall have prominence at least equal to that provided for other information presented                                              |
| equal to              | this chapter and shall have prominence at least equal to that provided for other information presented in the                                                                   |
| after                 | mutiple page advertisement, an asterisk shall be placed after the most prominent mention of the indi- cation(s);                                                                |
| after                 | mutiple page advertisement, an asterisk shall be placed after the most prominent mention of the indi- cation(s);                                                                |
| after                 | situations in direct correspondence with the drug promoters, after which the failure to make the disclosure will                                                                |
| within                | units of estrone activity is therefore considered misleading, within  the meaning of 21 U.S.C. 352(a).                                                                          |
| within                | are likely to swallow these products when left within  reach.                                                                                                                   |
| more than             | Food, Drug, and Cosmetic Act any drug containing more than 5 percent methyl salicylate (wintergreen oil), the labeling                                                          |
| within                | X-ray visualization is regarded as a new drug within the meaning of section 201(p) of the Federal                                                                               |
| within                | any shipments of tannic acid labeled to come within the exemptions under 502(f) of the Act containing                                                                           |
| within                | any shipments of tannic acid labeled to come within the exemptions under 502(f) of the Act containing                                                                           |
| within                | acid intended for use by man and found within the jurisdiction of the Federal Food, Drug, and                                                                                   |
| after                 | and Cosmetic Act labeled contrary to this section after 60 days from the date of its publication                                                                                |
| after                 | On the basis of the above information and after discussion with and concurrence of the Respiratory and                                                                          |
| prior to              | pharmacists to place the warning on the container prior to  dispensing.                                                                                                         |
| within                | publication of this section in the Federal Register: within                                                                                                                     |
| within                | The label and labeling of such preparations shipped within the jurisdiction of the act are in accordance                                                                        |
| within                | in paragraphs (b) and (c) of this section. within                                                                                                                               |
| after                 | an approved new-drug application is not in effect. after                                                                                                                        |
| within                | initiated with regard to any such drug shipped within the jurisdiction of the act for which an                                                                                  |
| within                | this statement of policy in the Federal Register: within                                                                                                                        |
| within                | (ii) The labeling on or  within the package from which the drug is to                                                                                                           |
| within                | with appropriate labeling as described in this paragraph. within                                                                                                                |
| after                 | Food and Drug Administration may initiate regulatory proceedings after 30 days from the date of publication of                                                                  |
| within                | Cosmetic Act; and (2) The labeling on or within the package from which the drug is to                                                                                           |
| prior to              | recommended and prescribed by physicians for bowel cleansing prior to  surgery and diagnostic procedures of the colon.                                                          |
| more than             | amount of sodium phosphates oral solution to not more than 90 mL (3 ounces (oz)) per OTC container                                                                              |
| within                | in paragraph (a) of this section is misbranded within the meaning of section 502 of the Federal                                                                                 |
| more than             | sodium phosphates oral solution: Container shall not contain more than  90 mL (3 oz).                                                                                           |
| more than             | &#8220;Taking  more than the recommended dose in 24 hours can be                                                                                                                |
| more than             | &#8220;Using  more than one enema in 24 hours can be harmful.&#8221;                                                                                                            |
| more than             | &#8220;Do not take  more than 45 mL (9 teaspoonfuls or 3 tablespoonfuls) in                                                                                                     |
| more than             | &#8220;Do not take  more than 20 mL (4 teaspoonfuls) in a 24-hour period.&#8221;                                                                                                |
| more than             | &#8220;Do not take  more than 10 mL (2 teaspoonfuls) in a 24-hour period.&#8221;                                                                                                |
| after                 | such drug product that is repackaged or relabeled after these dates regardless of the date the product                                                                          |
| after                 | such drug product that is repackaged or relabeled after these dates regardless of the date the product                                                                          |
| before                | the effect: &#8220;Warning&#8212;Keep out of reach of children. before                                                                                                          |
| more than             | Do not take  more than the recommended dosage, nor take regularly for longer                                                                                                    |
| within                | and Drugs will regard such preparations as misbranded within the meaning of section 502(f) (1) and (2)                                                                          |
| within                | and Drugs will regard such preparations as misbranded within the meaning of section 502(f) (1) and (2)                                                                          |
| within                | of phenindione intended for use by man found within the jurisdiction of the act on or after                                                                                     |
| after                 | within the jurisdiction of the act on or after November 25, 1961, unless such preparations are labeled                                                                          |
| first of              | is an aspirin preparation, it shall bear the first of  these warning statements.                                                                                                |
| more than             | distribution of such tablets in retail containers containing more than 36 tablets, to reduce the hazard of accidental                                                           |
| greater than          | for administration to children only of an age greater than 3 years (for example, the dosage instructions provide                                                                |
| more than             | to the effect: &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in                                                                             |
| exceed                | a physician immediately.&#8221; The salicylate dosage should not exceed 60 grains in a 24-hour period or 10                                                                     |
| more than             | (g)(1) The label of any drug containing  more than 5 percent methyl salicylate (wintergreen oil) should bear                                                                    |
| after                 | or initially delivered for introduction into interstate commerce after the following dates is misbranded under sections 201(n)                                                  |
| greater than          | as an active ingredient and have annual sales greater than  $25,000.                                                                                                            |
| less than             | as an active ingredient and have annual sales less than  $25,000.                                                                                                               |
| more than             | Do not use  more than 2 days or administer to children under 3                                                                                                                  |
| within                | human use with thyroid hormone activity are misbranded within the meaning of section 502 of the Federal                                                                         |
| within                | human use in oral dosage forms are misbranded within the meaning of section 502 of the Federal                                                                                  |
| within                | in paragraph (a) of this section are misbranded within the meaning of section 502 of the Federal                                                                                |
| after                 | pain, vomiting, or difficulty in swallowing or breathing after  taking this product, seek immediate medical attention;&#8221; and                                               |
| at least              | &#8220;Mix&#8221;) &#8220;this product (child or adult dose) with at least 8 ounces (a full glass) of water or                                                                  |
| after                 | such drug product that is repackaged or relabeled after this date regardless of the date the product                                                                            |
| after                 | such drug product that is repackaged or relabeled after this date regardless of the date the product                                                                            |
| after                 | be read by the physician (physician package insert) after the &#8220;How supplied&#8221; section, which describes special handling                                              |
| exceed                | in total parenteral nutrition (TPN) therapy must not exceed  25 micrograms per liter (&#181;g/L).                                                                               |
| no more than          | therapy must state that the drug product contains no more than  25 &#181;g/L of aluminum.                                                                                       |
| maximum               | provided in paragraph (d) of this section, the maximum level of aluminum present at expiry must be                                                                              |
| no more than          | aluminum content must be stated as follows: &#8220;Contains no more than __ &#181;g/L of aluminum.&#8221; The immediate container label                                         |
| no more than          | aluminum content must be stated as follows: &#8220;Contains no more than __ &#181;g/L of aluminum.&#8221; The immediate container label                                         |
| maximum               | will be no more than __ &#181;g/L.&#8221; This maximum level of aluminum must be stated as the                                                                                  |
| highest               | level of aluminum must be stated as the highest  of:                                                                                                                            |
|                       |               (1) The                                                                                                                                                           |
| highest               | level of aluminum must be stated as the highest  of:                                                                                                                            |
|                       |               (1) The                                                                                                                                                           |
| highest               | level of aluminum must be stated as the highest  of:                                                                                                                            |
|                       |               (1) The                                                                                                                                                           |
| maximum               | will be no more than __ &#181;g/L.&#8221; This maximum level of aluminum must be stated as the                                                                                  |
| after                 | completion of production of the first five batches after  July 26, 2004.                                                                                                        |
| maximum               | (d) If the  maximum level of aluminum is 25 &#181;g/L or less,                                                                                                                  |
| no more than          | section, the immediate container label may state: &#8220;Contains no more than 25 &#181;g/L of aluminum.&#8221; If the SVP or                                                   |
| no more than          | section, the immediate container label may state: &#8220;Contains no more than 25 &#181;g/L of aluminum.&#8221; If the SVP or                                                   |
| after                 | or initially delivered for introduction into interstate commerce after June 19, 2008, is misbranded under section 502                                                           |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| more than             | liver damage may occur if you take [bullet] more than [insert maximum number of daily dosage units] in                                                                          |
| maximum               | occur if you take [bullet] more than [insert maximum number of daily dosage units] in 24 hours,                                                                                 |
| maximum               | occur if you take [bullet] more than [insert maximum number of daily dosage units] in 24 hours,                                                                                 |
| after                 | acetaminophen and aspirin, this &#8220;Liver&#8221; warning must appear after the &#8220;Reye's syndrome&#8221; and &#8220;Allergy alert&#8221; warnings in                     |
| before                | &#8220;Allergy alert&#8221; warnings in &#167;&#8201;201.66(c)(5)(ii)(A) and (c)(5)(ii)(B) and before the &#8220;Stomach bleeding&#8221; warning in paragraph (a)(2)(iii)(A) of |
| before                | a doctor or pharmacist.&#8221; (C) &#8220;Ask a doctor before  use if you have liver disease&#8221;.                                                                            |
| before                | (D) &#8220;Ask a doctor or pharmacist  before use if you are taking the blood thinning                                                                                          |
| more than             | damage may occur if your child takes [bullet] more than 5 doses in 24 hours, which is the                                                                                       |
| maximum               | 5 doses in 24 hours, which is the maximum daily amount [optional: &#8216;for this product&#8217;] [bullet] with                                                                 |
| before                | a doctor or pharmacist.&#8221; (3) &#8220;Ask a doctor before  use if your child has liver disease&#8221;.                                                                      |
| before                | (4) &#8220;Ask a doctor or pharmacist  before use if your child is taking the blood                                                                                             |
| more than             | liver damage may occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in                                                                       |
| maximum               | occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in 24 hours,                                                                              |
| maximum               | occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in 24 hours,                                                                              |
| more than             | liver damage may occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in                                                                       |
| before                | (B) &#8220;Ask a doctor  before use if the user has liver disease.&#8221; (C)                                                                                                   |
| before                | or pharmacist.&#8221; (D) &#8220;Ask a doctor or pharmacist before use if the user is taking the blood                                                                          |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| after                 | as defined in &#167;&#8201;299.4 of this chapter, or after the general pharmacological (principal intended) action of the                                                       |
| after                 | as defined in &#167;&#8201;201.66(c)(2), contains the term &#8220;(NSAID*)&#8221; after the NSAID active ingredient with an asterisk statement                                  |
| after                 | This &#8220;Stomach bleeding&#8221; warning must appear  after the &#8220;Reye's syndrome&#8221; and &#8220;Allergy alert&#8221; warnings in                                    |
| before                | in paragraph (a)(1)(iii) of this section must appear before  the &#8220;Stomach bleeding&#8221; warning in this paragraph.                                                      |
| before                | (B) &#8220;Ask a doctor  before use if [bullet] stomach bleeding warning applies to                                                                                             |
| after                 | The &#8220;Stomach bleeding&#8221; warning must appear  after the &#8220;Reye's syndrome&#8221; and &#8220;Allergy alert&#8221; warnings in                                     |
| before                | (2) &#8220;Ask a doctor  before use if [bullet] stomach bleeding warning applies to                                                                                             |
| after                 | The &#8220;Stomach bleeding&#8221; warning must appear  after the &#8220;Reye's syndrome&#8220; and &#8220;Allergy alert&#8221; warnings in                                     |
| before                | (B) The labeling states &#8220;Ask a doctor  before use if [bullet] stomach bleeding warning applies to                                                                         |
| before                | or initially delivered for introduction into interstate commerce before or on April 29, 2010, must bear on                                                                      |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| at least              | the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2). at least                                                                                          |
| at least              | on the PDP of the drug product for at least 1 year from the date the product is                                                                                                 |
| at least              | without advance approval of FDA provided it includes at least the exact information included in paragraph (a) of                                                                |
| at least              | that are broad spectrum with SPF values of at least 2 but less than 15 according to the                                                                                         |
| less than             | with SPF values of at least 2 but less than 15 according to the SPF test in paragraph                                                                                           |
| before                | [and, as an option: &#8216;And evenly&#8217;] 15 minutes before  sun exposure&#8221;.                                                                                           |
| after                 | The labeling states &#8220;[bullet] reapply: [Bullet]  after [select one of the following determined by water                                                                   |
| after                 | The labeling states &#8220;[bullet] reapply: [Bullet]  after [select one of the following determined by water                                                                   |
| at least              | or sweating [bullet] immediately after towel drying [bullet] at least  every 2 hours&#8221;.                                                                                    |
| at least              | The labeling states &#8220;[bullet] reapply  at least every 2 hours [bullet] use a water resistant                                                                              |
| exceed                | UVA II (320-340 nm) irradiance should equal or exceed 20 percent of the total UV (290-400 nm)                                                                                   |
| exceed                | UVA I (340-400 nm) irradiance should equal or  exceed  60 percent of the total UV irradiance.                                                                                   |
| before                | The solar simulator output should be measured  before and after each phototest or, at a minimum,                                                                                |
| after                 | solar simulator output should be measured before and after each phototest or, at a minimum, at the                                                                              |
| minimum               | before and after each phototest or, at a minimum , at the beginning and end of each                                                                                             |
| after                 | time-related fluctuations (within 20 percent) in radiation emissions after an appropriate warm-up time and demonstrate good beam                                                |
| within                | simulator should have no significant time-related fluctuations ( within 20 percent) in radiation emissions after an appropriate                                                 |
| within                | dose to the UV exposure site must be within  10 percent of the expected dose.                                                                                                   |
| at least              | spectrum of the solar simulator should be measured at least annually with an appropriate and accurately calibrated spectroradiometer                                            |
| more than             | standard deviation in peak areas should not be more than  2.0 percent for either oxybenzone or padimate O.                                                                      |
| minimum of            | panel should include enough subjects to produce a minimum of  10 valid test results.                                                                                            |
| maximum of            | A  maximum of three subjects may be rejected from this panel                                                                                                                    |
| after                 | first 30 to 45 minutes of sun exposure after  a winter season of no sun exposure.                                                                                               |
| minimum of            | Each test site should be a  minimum of  30 square centimeters and outlined with indelible ink.                                                                                  |
| within                | the locations to which UV radiation is administered within  a test site.                                                                                                        |
| at least              | should receive UV doses within each test site. at least                                                                                                                         |
| within                | least five test subsites should receive UV doses within  each test site.                                                                                                        |
| at least              | Test subsites should be  at least 0.5 square centimeters (cm2) in area and should                                                                                               |
| at least              | Test subsites should be  at least 0.5 square centimeters (cm2) in area and should                                                                                               |
| at least              | Wait  at least 15 minutes after applying a sunscreen product before                                                                                                             |
| after                 | Wait at least 15 minutes  after applying a sunscreen product before exposing the test                                                                                           |
| before                | least 15 minutes after applying a sunscreen product before exposing the test sites to UV radiation as                                                                           |
| after                 | procedure described in paragraph (i)(7) of this section after  waiting at least 15 minutes.                                                                                     |
| at least              | in paragraph (i)(7) of this section after waiting at least  15 minutes.                                                                                                         |
| after                 | clearly defined borders at 16 to 24 hours after  UV exposure.                                                                                                                   |
| within                | (a)(2) of this section) to the test subsites within an unprotected test site using an accurately calibrated                                                                     |
| greater than          | by 1.25n (i.e., each dose is 25 percent greater than  the previous dose).                                                                                                       |
| less than             | For products with an expected SPF  less than 8, administer UV doses that increase by 25                                                                                         |
| after                 | are administered, all immediate responses should be recorded. after                                                                                                             |
| after                 | further UV radiation until the MED is determined. after                                                                                                                         |
| after                 | Determine the MED 16 to 24 hours  after  UV exposure.                                                                                                                           |
| after                 | Because erythema is evaluated 16 to 24 hours  after UV exposure, the final MEDu, ssMEDp, and tpMEDp                                                                             |
| at least              | tungsten or warm white fluorescent lighting that provides at least  450 lux of illumination at the test site.                                                                   |
| after                 | The labeled SPF should be determined  after 40 minutes of water immersion using the following                                                                                   |
| after                 | The labeled SPF should be determined  after 80 minutes of water immersion using the following                                                                                   |
| at least              | and must have a rectangular application area of at least 16 square centimeters (with no side shorter than                                                                       |
| less than or equal to | be set to provide a bandwidth that is less than or equal to  1 nanometer.                                                                                                       |
| greater               | for approximately 30 seconds followed by spreading with greater  pressure for approximately 30 seconds.                                                                         |
| before                | to equilibrate for 15 minutes in the dark before the pre-irradiation described in paragraph (c) of this                                                                         |
| after                 | the full UV spectrum (290 to 400 nanometers). after                                                                                                                             |
| at least              | glycerin (no sunscreen product) should be obtained from at least 5 different locations on the PMMA plate [C1(&#955;),                                                           |
| minimum of            | In addition, a  minimum of 5 measurements of spectral irradiance transmitted for each                                                                                           |
| after                 | with the sunscreen product will be similarly obtained after pre-irradiation of the sunscreen product [P1(&#955;), P2(&#955;), P3(&#955;),                                       |
| at least              | product, mean absorbance values should be determined from at least  three individual PMMA plates.                                                                               |
| at least              | Because paragraph (d) of this section requires  at least 5 measurements per plate, there should be a                                                                            |
| at least              | Because paragraph (d) of this section requires  at least 5 measurements per plate, there should be a                                                                            |
| within                | be attached to a medical gas supply system within a hospital, health care entity, nursing home, other                                                                           |
| at least              | of the gas on the label must be at least  2 inches high.                                                                                                                        |
| within                | this section if the gas or gases held within the container correspond to that color or those                                                                                    |


## Duration

| Duration    | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 12.0 month  | The regulations affecting special dietary foods (&#167;&#8201;105.3(e) of this chapter) define an infant as a child not more than 12 months old.                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1.0 year    | Some question has arisen whether, for the purposes of drug labeling, an infant means a child up to 1 year of age or a child up to 2 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2.0 year    | Some question has arisen whether, for the purposes of drug labeling, an infant means a child up to 1 year of age or a child up to 2 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 1.0 year    | Until the term is more precisely defined by legislation or formal regulation, where the exact meaning of the term is significant, manufacturers should qualify any reference to &#8220;infant&#8221; to indicate whether it refers to a child who is not more than 1 year of age, or a child not more than 2 years of age.                                                                                                                                                                                                                                                      |
| 2.0 year    | Until the term is more precisely defined by legislation or formal regulation, where the exact meaning of the term is significant, manufacturers should qualify any reference to &#8220;infant&#8221; to indicate whether it refers to a child who is not more than 1 year of age, or a child not more than 2 years of age.                                                                                                                                                                                                                                                      |
| 1.0 year    | A changed section must be listed under this heading in Highlights for at least 1 year after the date of the labeling change and must be removed at the first printing subsequent to the 1 year period.                                                                                                                                                                                                                                                                                                                                                                          |
| 1.0 year    | A changed section must be listed under this heading in Highlights for at least 1 year after the date of the labeling change and must be removed at the first printing subsequent to the 1 year period.                                                                                                                                                                                                                                                                                                                                                                          |
| 16.0 year   | (A) Pediatric population(s)/pediatric patient(s): For the purposes of paragraphs (c)(9)(iv)(B) through (c)(9)(iv)(H) of this section, the terms pediatric population(s) and pediatric patient(s) are defined as the pediatric age group, from birth to 16 years, including age groups often called neonates, infants, children, and adolescents.                                                                                                                                                                                                                                |
| 65.0 year   | Unless otherwise noted, information contained in the &#8220;Geriatric use&#8221; subsection must pertain to use of the drug in persons 65 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 30 second   | A common fraction shall be in terms of halves, quarters, eights, sixteenths, or thirty-seconds; except that if there exists a firmly established, general consumer usage and trade custom of employing different common fractions in the net quantity declaration of a particular commodity, they may be employed.                                                                                                                                                                                                                                                              |
| 12.0 year   | (iv) &#8220;Ask a doctor before use if you have&#8221; [in bold type] or, for products labeled only for use in children under 12 years of age, &#8220;Ask a doctor before use if the child has&#8221; [in bold type], followed by all warnings for persons with certain preexisting conditions (excluding pregnancy) and all warnings for persons experiencing certain symptoms.                                                                                                                                                                                                |
| 12.0 year   | (v) &#8220;Ask a doctor or pharmacist before use if you are&#8221; [in bold type] or, for products labeled only for use in children under 12 years of age, &#8220;Ask a doctor or pharmacist before use if the child is&#8221; [in bold type], followed by all drug-drug and drug-food interaction warnings.                                                                                                                                                                                                                                                                    |
| 1 second    | Under this heading the labeling shall identify one of the following categories that applies to the drug, and the labeling shall bear the statement required under the category:                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (a)  If adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of a risk in later trimesters), the labeling shall state: &#8220;Studies in pregnant women have not shown that (name of drug) increases the risk of fetal abnormalities if administered during the first (second, third, or all) trimester(s) of pregnancy.                                                                                                                           |
| 1 second    | Studies in pregnant women, however, have not shown that (name of drug) increases the risk of abnormalities when administered during the first (second, third, or all) trimester(s) of pregnancy.                                                                                                                                                                                                                                                                                                                                                                                |
| 16.0 year   | (i) Pediatric population(s)/pediatric patient(s): For the purposes of paragraphs (f)(9)(ii) through (f)(9)(viii) of this section, the terms pediatric population(s) and pediatric patient(s) are defined as the pediatric age group, from birth to 16 years, including age groups often called neonates, infants, children, and adolescents.                                                                                                                                                                                                                                    |
| 65.0 year   | Unless otherwise noted, information contained in the &#8220;Geriatric use&#8221; subsection of the labeling shall pertain to use of the drug in persons 65 years of age and older.                                                                                                                                                                                                                                                                                                                                                                                              |
| 2.0 year    | Such person and such operator shall each keep a copy of such agreement until 2 years after the final shipment or delivery of such drug from such establishment, and shall make such copies available for inspection at any reasonable hour to any officer or employee of the Department who requests them.                                                                                                                                                                                                                                                                      |
| 90.0 day    | (d) For new drugs and antibiotics, supplements to provide for revised labeling in accord with paragraph (c) of this section shall be submitted under the provisions of &#167;&#8201;314.70 and &#167;&#8201;514.8 of this chapter within 90 days after publication of the implementation notice in the Federal Register or by May 15, 1972, for those drugs for which notices have been published and such labeling shall be put into use as soon as possible but not later than the end of the time period allowed for submitting supplements to provide for revised labeling. |
| 60.0 day    | (c) Any tannic acid intended for use by man and found within the jurisdiction of the Federal Food, Drug, and Cosmetic Act labeled contrary to this section after 60 days from the date of its publication in the Federal Register may be made the subject of regulatory proceedings.                                                                                                                                                                                                                                                                                            |
| 30.0 day    | (1) Within 30 days following the date of publication of this section in the Federal Register:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 90.0 day    | (2) Within 90 days following the date of publication of this section in the Federal Register, the manufacturer, packer, or distributor of any drug containing isoproterenol intended for inhalation for which a new-drug approval is not in effect submits a new-drug application containing satisfactory information of the kinds required by &#167;&#8201;314.50 of this chapter, including appropriate labeling as described in paragraphs (b) and (c) of this section.                                                                                                      |
| 270.0 day   | (e) After 270 days following expiration of said 90 days, regulatory proceedings based on section 505(a) of the Federal Food, Drug, and Cosmetic Act may be initiated with regard to any such drug shipped within the jurisdiction of the act for which an approved new-drug application is not in effect.                                                                                                                                                                                                                                                                       |
| 90.0 day    | (e) After 270 days following expiration of said 90 days, regulatory proceedings based on section 505(a) of the Federal Food, Drug, and Cosmetic Act may be initiated with regard to any such drug shipped within the jurisdiction of the act for which an approved new-drug application is not in effect.                                                                                                                                                                                                                                                                       |
| 30.0 day    | (1) Within 30 days from the date of publication of this statement of policy in the Federal Register:                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 90.0 day    | (2) Within 90 days from the date of publication of this statement of policy in the Federal Register, the manufacturer, packer, or distributor of the drug shall submit a new-drug application containing satisfactory information of the kind required by &#167;&#8201;314.50 of this chapter, with appropriate labeling as described in this paragraph.                                                                                                                                                                                                                        |
| 30.0 day    | (b) The Food and Drug Administration may initiate regulatory proceedings after 30 days from the date of publication of this section, with respect to the marketing of uncoated tablets containing potassium chloride or other potassium salts which supply 100 milligrams or more of potassium per tablet or with respect to liquid preparations containing potassium chloride or other potassium salts which supply 20 milligrams or more of potassium per milliliter, labeled or intended for human use, unless all the following conditions are met:                         |
|             |               (1) The labeling of the drug bears the prescription statement quoted in section 503(b)(4) of the Federal Food, Drug, and Cosmetic Act; and                                                                                                                                                                                                                                                                                                                                                                                                                        |
|             |               (2) The labeling on or within the package from which the drug is to be dispensed bears adequate information for its use by practitioners in accord with the &#8220;full disclosure&#8221; labeling requirements of &#167;&#8201;201.100 of this chapter, including a recommendation that patients be directed to dissolve any such tablets in an appropriate amount of liquid and to dilute any such liquid preparations adequately to assure against gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations.     |
| 24.0 hour   | &#8220;Taking more than the recommended dose in 24 hours can be harmful.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (ii) Rectal enema dosage forms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 24.0 hour   | &#8220;Using more than one enema in 24 hours can be harmful.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|             |               (3) Directions&#8212;(i) The labeling of all orally or rectally administered OTC drug products containing sodium phosphates shall contain the following directions in boldface type immediately preceding the dosage information: &#8220;Do not&#8221; (&#8220;take&#8221; or &#8220;use&#8221;) &#8220;more unless directed by a doctor.                                                                                                                                                                                                                         |
| 12.0 year   | Adults and children 12 years of age and over: Oral dosage is dibasic sodium phosphate 3.42 to 7.56 grams (g) and monobasic sodium phosphate 9.1 to 20.2 g (20 to 45 mL dibasic sodium phosphate/monobasic sodium phosphate oral solution) as a single daily dose.                                                                                                                                                                                                                                                                                                               |
| 24.0 hour   | &#8220;Do not take more than 45 mL (9 teaspoonfuls or 3 tablespoonfuls) in a 24-hour period.&#8221; Children 10 and 11 years of age: Oral dosage is dibasic sodium phosphate 1.71 to 3.78 g and monobasic sodium phosphate 4.5 to 10.1 g (10 to 20 mL dibasic sodium phosphate/monobasic sodium phosphate oral solution) as a single daily dose.                                                                                                                                                                                                                                |
| 11.0 year   | &#8220;Do not take more than 45 mL (9 teaspoonfuls or 3 tablespoonfuls) in a 24-hour period.&#8221; Children 10 and 11 years of age: Oral dosage is dibasic sodium phosphate 1.71 to 3.78 g and monobasic sodium phosphate 4.5 to 10.1 g (10 to 20 mL dibasic sodium phosphate/monobasic sodium phosphate oral solution) as a single daily dose.                                                                                                                                                                                                                                |
| 24.0 hour   | &#8220;Do not take more than 20 mL (4 teaspoonfuls) in a 24-hour period.&#8221; Children 5 to 9 years of age: Oral dosage is dibasic sodium phosphate 0.86 to 1.89 g and monobasic sodium phosphate 2.2 to 5.05 g (5 to 10 mL dibasic sodium phosphate/monobasic sodium phosphate oral solution) as a single daily dose.                                                                                                                                                                                                                                                        |
| 9.0 year    | &#8220;Do not take more than 20 mL (4 teaspoonfuls) in a 24-hour period.&#8221; Children 5 to 9 years of age: Oral dosage is dibasic sodium phosphate 0.86 to 1.89 g and monobasic sodium phosphate 2.2 to 5.05 g (5 to 10 mL dibasic sodium phosphate/monobasic sodium phosphate oral solution) as a single daily dose.                                                                                                                                                                                                                                                        |
| 24.0 hour   | &#8220;Do not take more than 10 mL (2 teaspoonfuls) in a 24-hour period.&#8221; Children under 5 years of age: ask a doctor.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 5.0 year    | &#8220;Do not take more than 10 mL (2 teaspoonfuls) in a 24-hour period.&#8221; Children under 5 years of age: ask a doctor.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1.0 year    | Ordinarily, this drug should not be used if strychnine, corrosives such as alkalies (lye) and strong acids, or petroleum distillates such as kerosine, gasoline, coal oil, fuel oil, paint thinner, or cleaning fluid have been ingested.&#8221;                                                                                                                                                                                                                                                                                                                                |
|             |               (3) Usual dosage: 1 tablespoon (15 milliliters) in persons over 1 year of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 10.0 day    | Do not take more than the recommended dosage, nor take regularly for longer than 10 days without consulting your physician.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|             |             Phenindione; labeling of drug preparations intended for use by man.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 3.0 year    | (c) Aspirin tablets sold as such and containing no other active ingredients, except tablets which cannot be readily subdivided into a child's dose because of their coating or size, should always bear dosage directions for each age group down to 3 years of age, with a statement such as &#8220;For children under 3 years of age, consult your physician.&#8221; It is recommended that:                                                                                                                                                                                  |
|             |               (1) Aspirin tablets especially made for pediatric use be produced only in 11/4-grain size to reduce the hazard of errors in dosage;                                                                                                                                                                                                                                                                                                                                                                                                                               |
|             |               (2) By June 1, 1967, manufacturers and distributors of 11/4-grain size aspirin tablets discontinue the distribution of such tablets in retail containers containing more than 36 tablets, to reduce the hazard of accidental poisoning;                                                                                                                                                                                                                                                                                                                           |
|             |               (3) The flavoring of 5-grain aspirin tablets or other &#8220;adult aspirin tablets&#8221; be discontinued; and                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|             |               (4) Labeling giving undue emphasis to the pleasant flavor of flavored aspirin tablets be discontinued.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 3.0 year    | (c) Aspirin tablets sold as such and containing no other active ingredients, except tablets which cannot be readily subdivided into a child's dose because of their coating or size, should always bear dosage directions for each age group down to 3 years of age, with a statement such as &#8220;For children under 3 years of age, consult your physician.&#8221; It is recommended that:                                                                                                                                                                                  |
|             |               (1) Aspirin tablets especially made for pediatric use be produced only in 11/4-grain size to reduce the hazard of errors in dosage;                                                                                                                                                                                                                                                                                                                                                                                                                               |
|             |               (2) By June 1, 1967, manufacturers and distributors of 11/4-grain size aspirin tablets discontinue the distribution of such tablets in retail containers containing more than 36 tablets, to reduce the hazard of accidental poisoning;                                                                                                                                                                                                                                                                                                                           |
|             |               (3) The flavoring of 5-grain aspirin tablets or other &#8220;adult aspirin tablets&#8221; be discontinued; and                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|             |               (4) Labeling giving undue emphasis to the pleasant flavor of flavored aspirin tablets be discontinued.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 3.0 year    | (e)(1) It is the obligation of the distributor who labels a salicylate preparation for administration to children to make certain that the article is suitable for such use and labeled with adequate directions for use in the age group for which it is offered, but in no case should such an article bear directions for use in children under 3 years of age.                                                                                                                                                                                                              |
| 3.0 year    | If the directions provide for administration to children as young as 3 years of age, the label should bear the statement, &#8220;For children under 3 years of age consult your physician.&#8221; However, if the directions provide for administration to children only of an age greater than 3 years (for example, the dosage instructions provide for administration of the article to children only down to age 6), the label should bear a statement such as, &#8220;For younger children consult your physician.&#8221;                                                  |
|             |               (2) A statement such as, &#8220;For children under 3 years of age consult your physician&#8221; or &#8220;For younger children consult your physician&#8221; is not required on the label of an article clearly offered for administration to adults only.                                                                                                                                                                                                                                                                                                        |
| 3.0 year    | If the directions provide for administration to children as young as 3 years of age, the label should bear the statement, &#8220;For children under 3 years of age consult your physician.&#8221; However, if the directions provide for administration to children only of an age greater than 3 years (for example, the dosage instructions provide for administration of the article to children only down to age 6), the label should bear a statement such as, &#8220;For younger children consult your physician.&#8221;                                                  |
|             |               (2) A statement such as, &#8220;For children under 3 years of age consult your physician&#8221; or &#8220;For younger children consult your physician&#8221; is not required on the label of an article clearly offered for administration to adults only.                                                                                                                                                                                                                                                                                                        |
| 3.0 year    | If the directions provide for administration to children as young as 3 years of age, the label should bear the statement, &#8220;For children under 3 years of age consult your physician.&#8221; However, if the directions provide for administration to children only of an age greater than 3 years (for example, the dosage instructions provide for administration of the article to children only down to age 6), the label should bear a statement such as, &#8220;For younger children consult your physician.&#8221;                                                  |
|             |               (2) A statement such as, &#8220;For children under 3 years of age consult your physician&#8221; or &#8220;For younger children consult your physician&#8221; is not required on the label of an article clearly offered for administration to adults only.                                                                                                                                                                                                                                                                                                        |
| 3.0 year    | If the directions provide for administration to children as young as 3 years of age, the label should bear the statement, &#8220;For children under 3 years of age consult your physician.&#8221; However, if the directions provide for administration to children only of an age greater than 3 years (for example, the dosage instructions provide for administration of the article to children only down to age 6), the label should bear a statement such as, &#8220;For younger children consult your physician.&#8221;                                                  |
|             |               (2) A statement such as, &#8220;For children under 3 years of age consult your physician&#8221; or &#8220;For younger children consult your physician&#8221; is not required on the label of an article clearly offered for administration to adults only.                                                                                                                                                                                                                                                                                                        |
| 10.0 day    | The label and labeling should bear in juxtaposition with such directions for use conspicuous warning statements to the effect: &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately.&#8221; The salicylate dosage should not exceed 60 grains in a 24-hour period or 10 grains in a 4-hour period.                                                                                                                                                         |
| 12.0 year   | The label and labeling should bear in juxtaposition with such directions for use conspicuous warning statements to the effect: &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately.&#8221; The salicylate dosage should not exceed 60 grains in a 24-hour period or 10 grains in a 4-hour period.                                                                                                                                                         |
| 24.0 hour   | The label and labeling should bear in juxtaposition with such directions for use conspicuous warning statements to the effect: &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately.&#8221; The salicylate dosage should not exceed 60 grains in a 24-hour period or 10 grains in a 4-hour period.                                                                                                                                                         |
| 4.0 hour    | The label and labeling should bear in juxtaposition with such directions for use conspicuous warning statements to the effect: &#8220;Caution: If pain persists for more than 10 days, or redness is present, or in conditions affecting children under 12 years of age, consult a physician immediately.&#8221; The salicylate dosage should not exceed 60 grains in a 24-hour period or 10 grains in a 4-hour period.                                                                                                                                                         |
| 2.0 day     | Do not use more than 2 days or administer to children under 3 years of age unless directed by physician.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |             Drugs with thyroid hormone activity for human use; required warning.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 3.0 year    | Do not use more than 2 days or administer to children under 3 years of age unless directed by physician.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |             Drugs with thyroid hormone activity for human use; required warning.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 3.0 year    | The aluminum content must be stated as follows: &#8220;Contains no more than __ &#181;g/L of aluminum.&#8221; The immediate container label of all SVP's and PBP's that are lyophilized powders used in the preparation of TPN solutions must contain the following statement: &#8220;When reconstituted in accordance with the package insert instructions, the concentration of aluminum will be no more than __ &#181;g/L.&#8221; This maximum level of aluminum must be stated as the highest of:                                                                           |
|             |               (1) The highest level for the batches produced during the last 3 years;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|             |               (2) The highest level for the latest five batches, or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|             |               (3) The maximum historical level, but only until completion of production of the first five batches after July 26, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1 quarter   | The ingredient name &#8220;acetaminophen&#8221; must appear highlighted (e.g., fluorescent or color contrast) or in bold type, be in lines generally parallel to the base on which the package rests as it is designed to be displayed, and be in one of the following sizes, whichever is greater:                                                                                                                                                                                                                                                                             |
|             |               (A) At least one-quarter as large as the size of the most prominent printed matter on the principal display panel (PDP), or                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|             |               (B) At least as large as the size of the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2).                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 24.0 hour   | Severe liver damage may occur if you take [bullet] more than [insert maximum number of daily dosage units] in 24 hours, which is the maximum daily amount [optional: &#8216;for this product&#8217;] [bullet] with other drugs containing acetaminophen [bullet] 3 or more alcoholic drinks every day while using this product&#8221;.                                                                                                                                                                                                                                          |
| 12.0 year   | (iv) For products labeled only for children under 12 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 24.0 hour   | Severe liver damage may occur if your child takes [bullet] more than 5 doses in 24 hours, which is the maximum daily amount [optional: &#8216;for this product&#8217;] [bullet] with other drugs containing acetaminophen&#8221;.                                                                                                                                                                                                                                                                                                                                               |
| 12.0 year   | (v) For products labeled for adults and children under 12 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 24.0 hour   | Severe liver damage may occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in 24 hours, which is the maximum daily amount [optional: &#8216;for this product&#8217;] [bullet] child takes more than 5 doses in 24 hours [bullet] taken with other drugs containing acetaminophen [bullet] adult has 3 or more alcoholic drinks everyday while using this product.&#8221; If there is an outer and immediate container of a retail package, this warning must appear on both the outer and immediate containers.                              |
| 24.0 hour   | Severe liver damage may occur if [bullet] adult takes more than [insert maximum number of daily dosage units] in 24 hours, which is the maximum daily amount [optional: &#8216;for this product&#8217;] [bullet] child takes more than 5 doses in 24 hours [bullet] taken with other drugs containing acetaminophen [bullet] adult has 3 or more alcoholic drinks everyday while using this product.&#8221; If there is an outer and immediate container of a retail package, this warning must appear on both the outer and immediate containers.                              |
| 1 quarter   | The word &#8220;(NSAID)&#8221; must appear highlighted (e.g., fluorescent or color contrast) or in bold type, be in lines generally parallel to the base on which the package rests as it is designed to be displayed, and be in one of the following sizes, whichever is greater:                                                                                                                                                                                                                                                                                              |
|             |               (A) At least one-quarter as large as the size of the most prominent printed matter on the PDP, or                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (B) At least as large as the size of the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2).                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 12.0 year   | (iv) For products labeled only for children under 12 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 12.0 year   | (v) For products labeled for adults and children under 12 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1 quarter   | This statement must appear highlighted (e.g., fluorescent or color contrast) or in bold type, be in lines generally parallel to the base on which the package rests as it is designed to be displayed, and be in one of the following sizes, whichever is greater:                                                                                                                                                                                                                                                                                                              |
|             |               (1) At least one-quarter as large as the size of the most prominent printed matter on the PDP, or                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|             |               (2) At least as large as the size of the &#8220;Drug Facts&#8221; title, as required in &#167;&#8201;201.66(d)(2).                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 1.0 year    | The new warnings information statement must remain on the PDP of the drug product for at least 1 year from the date the product is initially introduced into interstate commerce.                                                                                                                                                                                                                                                                                                                                                                                               |
| 40.0 minute | (2) Water resistance statements&#8212;(i) For products that provide 40 minutes of water resistance according to the test in paragraph (i)(7)(i) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                |
| 40.0 minute | The labeling states &#8220;Water Resistant (40 minutes)&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 80.0 minute | (ii) For products that provide 80 minutes of water resistance according to the test in paragraph (i)(7)(ii) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 80.0 minute | The labeling states &#8220;Water Resistant (80 minutes)&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 15.0 minute | (ii) The labeling states &#8220;[bullet] apply [select one of the following: &#8216;Liberally&#8217; or &#8216;generously&#8217;] [and, as an option: &#8216;And evenly&#8217;] 15 minutes before sun exposure&#8221;.                                                                                                                                                                                                                                                                                                                                                          |
| 6.0 month   | (iv) The labeling states &#8220;[bullet] children under 6 months of age: Ask a doctor&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 40.0 minute | The labeling states &#8220;[bullet] reapply: [Bullet] after [select one of the following determined by water resistance test: &#8216;40 minutes of&#8217; or &#8216;80 minutes of&#8217;] swimming or sweating [bullet] immediately after towel drying [bullet] at least every 2 hours&#8221;.                                                                                                                                                                                                                                                                                  |
| 80.0 minute | The labeling states &#8220;[bullet] reapply: [Bullet] after [select one of the following determined by water resistance test: &#8216;40 minutes of&#8217; or &#8216;80 minutes of&#8217;] swimming or sweating [bullet] immediately after towel drying [bullet] at least every 2 hours&#8221;.                                                                                                                                                                                                                                                                                  |
| 2.0 hour    | The labeling states &#8220;[bullet] reapply: [Bullet] after [select one of the following determined by water resistance test: &#8216;40 minutes of&#8217; or &#8216;80 minutes of&#8217;] swimming or sweating [bullet] immediately after towel drying [bullet] at least every 2 hours&#8221;.                                                                                                                                                                                                                                                                                  |
| 2.0 hour    | The labeling states &#8220;[bullet] reapply at least every 2 hours [bullet] use a water resistant sunscreen if swimming or sweating&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 45.0 minute | (B) Skin type is based on first 30 to 45 minutes of sun exposure after a winter season of no sun exposure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 15.0 minute | Wait at least 15 minutes after applying a sunscreen product before exposing the test sites to UV radiation as described in paragraph (i)(5)) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 15.0 minute | For water resistant sunscreen products, proceed with the water resistance testing procedure described in paragraph (i)(7) of this section after waiting at least 15 minutes.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 24.0 hour   | The minimal erythema dose (MED) is the smallest UV dose that produces perceptible redness of the skin (erythema) with clearly defined borders at 16 to 24 hours after UV exposure.                                                                                                                                                                                                                                                                                                                                                                                              |
| 60.0 minute | These may include an immediate darkening or tanning, typically grayish or purplish in color, which fades in 30 to 60 minutes; an immediate reddening at the subsite, due to heating of the skin, which fades rapidly; and an immediate generalized heat response, spreading beyond the subsite, which fades in 30 to 60 minutes.                                                                                                                                                                                                                                                |
| 60.0 minute | These may include an immediate darkening or tanning, typically grayish or purplish in color, which fades in 30 to 60 minutes; an immediate reddening at the subsite, due to heating of the skin, which fades rapidly; and an immediate generalized heat response, spreading beyond the subsite, which fades in 30 to 60 minutes.                                                                                                                                                                                                                                                |
| 24.0 hour   | Determine the MED 16 to 24 hours after UV exposure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 24.0 hour   | Because erythema is evaluated 16 to 24 hours after UV exposure, the final MEDu, ssMEDp, and tpMEDp are typically determined the day following determination of the initial MEDu.                                                                                                                                                                                                                                                                                                                                                                                                |
| 40.0 minute | (i) Water resistance (40 minutes).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 40.0 minute | The labeled SPF should be determined after 40 minutes of water immersion using the following procedure:                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|             |               (A) Step 1: Apply the sunscreen as described in paragraph (d) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 20.0 minute | (B) Step 2: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 minute | (C) Step 3: Rest out of water for 15 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 20.0 minute | (D) Step 4: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 80.0 minute | (ii) Water resistance (80 minutes).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 80.0 minute | The labeled SPF should be determined after 80 minutes of water immersion using the following procedure:                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|             |               (A) Step 1: Apply the sunscreen as described in paragraph (d) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 20.0 minute | (B) Step 2: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 minute | (C) Step 3: Rest out of water for 15 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 20.0 minute | (D) Step 4: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 minute | (E) Step 5: Rest out of water for 15 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 20.0 minute | (F) Step 6: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 15.0 minute | (G) Step 7: Rest out of water for 15 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 20.0 minute | (H) Step 8: Perform moderate activity in water for 20 minutes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 30.0 second | Spreading should be done with a very light spreading action for approximately 30 seconds followed by spreading with greater pressure for approximately 30 seconds.                                                                                                                                                                                                                                                                                                                                                                                                              |
| 30.0 second | Spreading should be done with a very light spreading action for approximately 30 seconds followed by spreading with greater pressure for approximately 30 seconds.                                                                                                                                                                                                                                                                                                                                                                                                              |
| 15.0 minute | The plate should then be allowed to equilibrate for 15 minutes in the dark before the pre-irradiation described in paragraph (c) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                               |


## Condition

| Condition      | Context                                                                                                                                                          |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| if             | section 502 (a) and (b)(1) of the act if its label does not bear conspicuously the name                                                                          |
| if             | in paragraph (b) of this section and ident if ies by appropriate designation all other persons who                                                               |
| if             | in paragraph (b) of this section and ident if ies by appropriate designation all other persons who                                                               |
| if             | in paragraph (b) of this section and ident if ies by appropriate designation all other persons who                                                               |
| if             | in paragraph (b) of this section and ident if ies by appropriate designation all other persons who                                                               |
| if             | in paragraph (b) of this section and ident if ies by appropriate designation all other persons who                                                               |
| when           | For purposes of this paragraph, person,  when it identifies a corporation, includes a parent, subsidiary,                                                        |
| where          | corporation, includes a parent, subsidiary, or affiliate company where the related companies are under common ownership and                                      |
| if             | listed in paragraph (b) of this section only if the operation is performed, including the performance of                                                         |
| subject to     | and, throughout the performance of the operation, are subject to the person's direction and control; (2) On premises                                             |
| subject to     | and, throughout the performance of the operation, are subject to the person's direction and control; (2) On premises                                             |
| when           | As used in this paragraph, person,  when it identifies a corporation, includes a parent, subsidiary,                                                             |
| where          | corporation, includes a parent, subsidiary, or affiliate company where the related companies are under common ownership and                                      |
| where          | name of a parent, subsidiary, or affiliate company where the related companies are under common ownership and                                                    |
| where          | name of a parent, subsidiary, or affiliate company where the related companies are under common ownership and                                                    |
| if             | is misbranded under section 502(a) of the act, if the person is not the manufacturer of the                                                                      |
| if             | drug or drug product, the label may ident if y which of the persons is to be                                                                                     |
| if             | (e.g., tablet or capsule), the label may ident if y the holder or licensee of the trademark.                                                                     |
| if             | on the label, the name shall be qual if ied by one of the following phrases: &#8220;Manufactured                                                                 |
| if             | (6) If the packer is ident if ied on the label, the name shall be                                                                                                |
| if             | The street address may be omitted  if it is shown in a current city directory                                                                                    |
| if             | be distributed, unless such statement would be misleading. if                                                                                                    |
| where          | of business in lieu of the actual place where such drug or drug product was manufactured or                                                                      |
| unless         | manufactured or packed or is to be distributed, unless  such statement would be misleading.                                                                      |
| if             | is misbranded under section 502(a) of the act if  its labeling ident                                                                                             |
| subject to     | not apply to biological drug products that are subject to the requirements of section 351 of the Public                                                          |
| when           | respect to, an ingredient present in such drug, when such proportion or other fact is material in                                                                |
| when           | or ingredient has some unique effectiveness or composition when , in fact, the drug or ingredient is                                                             |
| when           | or ingredient has some unique effectiveness or composition when , in fact, the drug or ingredient is                                                             |
| if             | quantity of such ingredient in each such unit. if                                                                                                                |
| if             | percentage of an ingredient in a drug shall, if  the term percent is used without qual                                                                           |
| if             | percentage of an ingredient in a drug shall, if  the term percent is used without qual                                                                           |
| if             | percentage of an ingredient in a drug shall, if  the term percent is used without qual                                                                           |
| if             | ),  if the ingredient is a solid and the drug                                                                                                                    |
| if             | ),  if both the ingredient and the drug are liquids,                                                                                                             |
| if             | a derivative or preparation of a substance spec if ically named in section 502(e) of the act                                                                     |
| if             | drug or any ingredient thereof, the established name, if such there be, corresponding to such proprietary name                                                   |
| if             | drug or any ingredient thereof, the established name, if such there be, corresponding to such proprietary name                                                   |
| if             | used in such running text: Provided, however, That if the proprietary name or designation is used in                                                             |
| if             | such column of running text: Provided, however, That if the proprietary name or designation is used in                                                           |
| if             | prescription drug containing two or more active ingredients, if the label bears a proprietary name or designation                                                |
| if             | the size and prominence of the front-panel display. if                                                                                                           |
| if             | name of the drug; (ii) The established name, if such there be, of the drug; (iii) An                                                                             |
| if             | name of the drug; (ii) The established name, if such there be, of the drug; (iii) An                                                                             |
| if             | (b) or (e) of the act, shall apply if such insufficiency is caused by: (1) The use                                                                               |
| where          | Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English,                                                          |
| if             | label shall appear thereon in the foreign language. if                                                                                                           |
| if             | appear on the labeling in the foreign language. if                                                                                                               |
| where          | for distribution in the Commonwealth of Puerto Rico where  Spanish is the predominant language.                                                                  |
| if             | the immediate container and also the outer package, if any, unless it is easily legible through such                                                             |
| unless         | container and also the outer package, if any, unless  it is easily legible through such outer package.                                                           |
| when           | However,  when single-dose containers are packed in individual cartons, the                                                                                      |
| where          | more precisely defined by legislation or formal regulation, where the exact meaning of the term is significant,                                                  |
| subject to     | The labels of certain drug products  subject to this labeling requirement that are also cosmetics, such                                                          |
| subject to     | The labels of certain drug products  subject to this labeling requirement that are also cosmetics, such                                                          |
| when           | Food and Drug Administration has determined that aspartame when used at a level no higher than reasonably                                                        |
| when           | use containing a sulfite, except epinephrine for injection when intended for use in allergic or other emergency                                                  |
| unless         | populations for whom a pediatric formulation is necessary, unless the manufacturer demonstrates that reasonable attempts to produce                              |
| if             | in the form of a letter, after not if ying the manufacturer of its intent to require                                                                             |
| if             | the requirements of paragraph (a) of this section if  the applicant cert                                                                                         |
| if             | of this section with respect to a spec if ied pediatric age group,                                                                                               |
| if             | grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable                                                                   |
| if             | (a) of this section within the time spec if ied by FDA, the drug product may be                                                                                  |
| subject to     | (a) Who is  subject to  these bar code requirements?                                                                                                             |
| subject to     | Act or the Public Health Service Act are subject to these bar code requirements unless they are exempt                                                           |
| unless         | Act are subject to these bar code requirements unless they are exempt from the registration and drug                                                             |
| subject to     | (b) What drugs are  subject to  these bar code requirements?                                                                                                     |
| subject to     | The following drug products are  subject to the bar code label requirements: (1) Prescription drug                                                               |
| subject to     | are sold to or used in hospitals are subject to  the bar code requirements.                                                                                      |
| if             | OTC drug product is &#8220;commonly used in hospitals&#8221; if it is packaged for hospital use, labeled for                                                     |
| if             | and not explicitly required by statute, for spec if ied lots, batches, or other units of a                                                                       |
| subject to     | of the human drug product that would be subject to the exception or alternative; (ii) Identify the labeling                                                      |
| subject to     | of the human drug product that would be subject to the exception or alternative; (ii) Identify the labeling                                                      |
| subject to     | Center Director so that the labeling of product subject to the exception or alternative includes the information necessary                                       |
| if             | or &#167;&#8201;601.12(f)(1) through (f)(2) of this chapter; however, if                                                                                         |
| if             | dosage forms shall be in terms of weight if the drug is solid, semi-solid, or viscous, or                                                                        |
| if             | dosage forms shall be in terms of weight if the drug is solid, semi-solid, or viscous, or                                                                        |
| when           | each active ingredient in each drug unit or, when quantity does not accurately reflect drug potency, a                                                           |
| if             | the net quantity declaration required by this section if it is an ointment labeled &#8220;sample&#8221;, &#8220;physician's sample&#8221;,                       |
| when           | view of the Food and Drug Administration that when such a situation prevails, compliance with this requirement                                                   |
| where          | such as &#8220;See package insert for dosage information&#8221;, where  the detailed information is contained in such insert.                                    |
| if             | However,  if an informative, realistic, recommended or usual dosage can                                                                                          |
| when           | of this chapter, the labeling must be updated when new information becomes available that causes the labeling                                                    |
| if             | or suggestions of drug use may be made if there is inadequate evidence of safety or a                                                                            |
| subject to     | (b) Categories of prescription drugs  subject to the labeling content and format requirements in &#167;&#167;&#8201;201.56(d)                                    |
| subject to     | The following categories of prescription drug products are subject to the labeling requirements in paragraph (d) of this                                         |
| subject to     | described in paragraph (b)(1) of this section are subject to the labeling requirements in paragraph (e) of this                                                  |
| if             | labeling may contain the following additional section headings if  appropriate and                                                                               |
| if             | labeling may contain the following additional section headings if  appropriate and                                                                               |
| if             | name and the established name of the drug, if any, as defined in section 502(e)(3) of the                                                                        |
| if             | The heading(s) and,  if appropriate, the subheading(s) of the labeling section(s) affected                                                                       |
| if             | not be repeated under this heading in Highlights if they are included elsewhere in Highlights (e.g., Warnings                                                    |
| if             | statement &#8220;See 17 for Patient Counseling Information&#8221; or, if the product has FDA-approved patient labeling, the verbatim                             |
| if not         | required in the full prescribing information under &#167;&#8201;201.56(d)(1), if not omitted under &#167;&#8201;201.56(d)(4), preceded by the identifying number |
| unless         | headings, subheadings, and identifying numbers required under &#167;&#8201;201.56(d)(1), unless  omitted under &#167;&#8201;201.56(d)(4).                        |
| when           | (i) This section must include the following information  when the conditions listed are applicable: (A) If the                                                   |
| if             | as an adjunct to that mode of therapy. if                                                                                                                        |
| if             | or patients in a special age group), or if the indication is approved based on a surrogate                                                                       |
| if             | or patients in a special age group), or if the indication is approved based on a surrogate                                                                       |
| if             | (C) If spec if ic tests are necessary for selection or monitoring                                                                                                |
| if             | treatment should be limited, or to any mod if ication of dosage, a concise description of the                                                                    |
| when           | between doses, to the appropriate duration of treatment when such treatment should be limited, or to any                                                         |
| if             | that the drug should be reserved for spec if ic situations (e.g., cases refractory to other drugs),                                                              |
| if             | (F) If there are spec if ic conditions that should be met before the                                                                                             |
| if             | (F) If there are spec if ic conditions that should be met before the                                                                                             |
| if             | may be effective for a certain use or if there is a common use of the drug                                                                                       |
| if             | may be effective for a certain use or if there is a common use of the drug                                                                                       |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless this requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)             |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless the requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)              |
| if not         | or suggested in other sections of the labeling if not  included in this section.                                                                                 |
| if not         | or suggested in other sections of the labeling if not  included in this section.                                                                                 |
| when           | titrating dosage, (F) The usual duration of treatment when treatment duration should be limited, (G) Dosing recommendations                                      |
| if             | based on clinical pharmacologic data (e.g., clinically sign if icant food effects),                                                                              |
|                |               (H) Mod                                                                                                                                            |
| when           | (TDM) must also be included in this section when  TDM is necessary.                                                                                              |
| if not         | or suggested in other sections of the labeling if not  included in this section.                                                                                 |
| when           | (including the strength of the final dosage solution, when prepared according to instructions, in terms of milligrams                                            |
| unless         | of active ingredient per milliliter of reconstituted solution, unless another measure of the strength is more appropriate),                                      |
| if             | (iv) This section must also contain spec if ic direction on dilution, preparation (including the strength                                                        |
| when           | (including the strength of the final dosage solution, when prepared according to instructions, in terms of milligrams                                            |
| if             | (iv) This section must also contain spec if ic direction on dilution, preparation (including the strength                                                        |
| if             | in metric system (e.g., 10 milligram tablets), and, if the apothecary system is used, a statement of                                                             |
| when           | forms, including shape, color, coating, scoring, and imprinting, when  applicable.                                                                               |
| if             | and not theoretical possibilities must be listed (e.g., if severe hypersensitivity to the drug has not been                                                      |
| if             | This section must describe clinically sign if icant adverse reactions (including any that are potentially                                                        |
| if             | This section must describe clinically sign if icant adverse reactions (including any that are potentially                                                        |
| if             | The frequency of all clinically sign if icant adverse reactions and the approximate mortality and                                                                |
| as soon as     | include a warning about a clinically significant hazard as soon as there is reasonable evidence of a causal association                                          |
| if             | A spec if ic warning relating to a use not provided                                                                                                              |
| where          | product with laboratory tests and reference the section where the detailed information is presented (e.g., &#8220;Drug Interactions&#8221;                       |
| if             | the same pharmacologically active and chemically related class, if  applicable.                                                                                  |
| unless         | drug and comparators (e.g., placebo) must be presented, unless such data cannot be determined or presentation of                                                 |
| if             | database), adverse reactions must be grouped within spec if ied frequency ranges as appropriate to the safety                                                    |
| if             | For adverse reactions with sign if icant clinical implications, the listings must be supplemented                                                                |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless this requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)             |
| if             | The mechanism(s) of the interaction,  if  known, must be briefly described.                                                                                      |
| when           | The Risk Summary must state  when  there are no human data or                                                                                                    |
| when           | The Risk Summary must state  when  there are no human data or                                                                                                    |
| if             | adverse reaction that is unique to pregnancy or if a known adverse reaction occurs with increased frequency                                                      |
| if             | The labeling must describe,  if known, the effect of dose, timing, and duration                                                                                  |
| if             | The labeling must describe,  if known, the effect of dose, timing, and duration                                                                                  |
| unless         | are available, animal data must not be included unless the animal model is specifically known to be                                                              |
| if             | compared to the labeled infant or pediatric dose, if  available, or to the maternal dose.                                                                        |
| unless         | For drugs absorbed systemically,  unless breastfeeding is contraindicated during drug therapy, the following                                                     |
| when           | recommended before, during, or after drug therapy and/or when there are human and/or animal data that suggest                                                    |
| if             | (B) If there is a spec if ic pediatric indication d                                                                                                              |
| if             | this subsection should be discussed in more detail, if appropriate, under the &#8220;Clinical Pharmacology&#8221; or &#8220;Clinical Studies&#8221;              |
| if             | (C) If there are spec if ic statements on pediatric use of the drug                                                                                              |
| if             | (C) If there are spec if ic statements on pediatric use of the drug                                                                                              |
| when           | the &#8220;Clinical Pharmacology&#8221; or the &#8220;Clinical Studies&#8221; section. when                                                                      |
| if             | this subsection must be discussed in more detail, if appropriate, under the &#8220;Clinical Pharmacology&#8221; or the &#8220;Clinical                           |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard must be described in                                                                |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard must be described in                                                                |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard must be described in                                                                |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard must be described in                                                               |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard must be described in                                                               |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard must be described in                                                               |
| if             | of the statements and may propose alternative statement(s). if                                                                                                   |
| if             | FDA may permit use of an alternative statement  if FDA determines that no statement described in those                                                           |
| if             | in the &#8220;Contraindications&#8221; or &#8220;Warnings and Precautions&#8221; section. if                                                                     |
| if             | (A) A spec if ic geriatric indication,                                                                                                                           |
| if             | this subsection must be discussed in more detail, if appropriate, under &#8220;Clinical Pharmacology&#8221; or the &#8220;Clinical Studies&#8221;                |
| if             | over to determine whether elderly subjects respond d if ferently from younger subjects, and other reported clinical                                              |
| if             | elderly subjects to make it likely that d if ferences in safety or effectiveness between elderly and                                                             |
| if             | elderly subjects to make it likely that d if ferences in safety or effectiveness between elderly and                                                             |
| if             | (C)(1) If spec if ic pharmacokinetic or pharmacodynamic studies have been carried                                                                                |
| if             | in the elderly appears to cause a spec if ic hazard, the hazard must be described in                                                                             |
| if             | in the elderly appears to cause a spec if ic hazard, the hazard must be described in                                                                             |
| if             | in the elderly appears to cause a spec if ic hazard, the hazard must be described in                                                                             |
| if             | through (c)(9)(v)(C) of this section may include statements, if they are necessary for safe and effective use                                                    |
| if             | through (c)(9)(v)(C) of this section may include statements, if they are necessary for safe and effective use                                                    |
| if             | FDA may permit omission of the statements  if FDA determines that no statement described in those                                                                |
| if             | FDA may permit use of an alternative statement  if the agency determines that such statement is accurate                                                         |
| if             | Additional subsections may be included, as appropriate,  if sufficient data are available concerning the use of                                                  |
| if             | &#8220;Clinical Pharmacology&#8221; section also may be referenced here, if applicable to overdoses; (iv) The amount of the                                      |
| if             | (A) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | (A) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | (A) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | as physical constants or pH, must be stated. if                                                                                                                  |
| if             | interaction studies), may be included in this section if essential to understand dosing or drug interaction information                                          |
| if             | response (including short-term clinical response) must be included if  known.                                                                                    |
| if             | (renal, hepatic, total), mechanisms of clearance (e.g., spec if ic enzyme systems), drug/drug and drug/food (e.g., dietary                                       |
| if             | (plasma protein, erythrocyte) parameters must also be presented if  clinically sign                                                                              |
| if             | vitro data for anti-infective drugs may be included if the data are immediately preceded by the statement                                                        |
| if             | vitro data for anti-infective drugs may be included if the data are immediately preceded by the statement                                                        |
| if             | have been performed to evaluate carcinogenic potential and, if  so, the species and results.                                                                     |
| where          | refer to the other sections of the labeling where  the risk is identified or discussed.                                                                          |
| if             | in metric system (e.g., 10 milligram tablets) and, if the apothecary system is used, a statement of                                                              |
| subject to     | following this section or accompanying the labeling is subject to the type size requirements in paragraph (d)(6) of                                              |
| subject to     | Medication Guides for distribution to patients are  subject to the type size requirements set forth in &#167;&#8201;208.20                                       |
| if             | subheading must be preceded by a bullet point. if                                                                                                                |
| if             | be limited in length to an amount that, if printed in 2 columns on a standard sized                                                                              |
| if             | Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, or, if applicable, the Director (or the Director's designee), Food                                        |
| where          | (a) In the case of a rectangular package where one entire side properly can be considered to                                                                     |
| where          | total surface of the container: Provided, however, That where such container presents an obvious &#8220;principal display panel&#8221;                           |
| if             | terms of the established name of the drug, if any there be, followed by an accurate statement                                                                    |
| if             | dosage forms shall be in terms of weight if the drug is solid, semisolid, or viscous, or                                                                         |
| if             | dosage forms shall be in terms of weight if the drug is solid, semisolid, or viscous, or                                                                         |
| when           | The drug quantity statement shall be augmented  when necessary to give accurate information as to the                                                            |
| when           | Such term shall be augmented  when necessary for accuracy of information by a statement                                                                          |
| if             | halves, quarters, eights, sixteenths, or thirty-seconds; except that if there exists a firmly established, general consumer usage                                |
| when           | area of the label panel shall not apply when the declaration of net quantity of contents meets                                                                   |
| when           | quantity of the contents that will be expelled when the instructions for use as shown on the                                                                     |
| when           | on a glass or plastic surface is permissible when all label information is so formed on the                                                                      |
| when           | numeral shall meet one-half the minimum height standards. when                                                                                                   |
| if             | except not less than one-half inch in height if  the area is more than 400 square inches.                                                                        |
| if             | shall be expressed both in ounces, with ident if ication by weight or by liquid measure and,                                                                     |
| when           | The term net weight shall be used  when stating the net quantity of contents in terms                                                                            |
| if             | be expressed both in terms of inches and, if applicable (1 foot or more), the largest whole                                                                      |
| if             | or decimal fractions of the foot or yard; if applicable, as in the case of adhesive tape,                                                                        |
| if             | expressed both in terms of square inches and, if applicable (1 square foot or more), the largest                                                                 |
| provided that  | in nondeceptive terms the net quantity of contents, provided that such supplemental statements of net quantity of contents                                       |
| if             | the net quantity declaration required by this section if it is an ointment labeled &#8220;sample,&#8221; &#8220;physician's sample,&#8221;                       |
| unless         | drug products that are intended for systemic absorption, unless specifically exempted, shall contain a general warning under                                     |
| if             | that are intended for systemic absorption, unless spec if ically exempted, shall contain a general warning under                                                 |
| where          | NDA or in the final OTC drug monograph. where                                                                                                                    |
| unless         | the warning in paragraph (a) of this section, unless otherwise stated in the NDA or in the                                                                       |
| where          | an exemption from paragraph (a) of this section where appropriate upon petition under the provisions of &#167;&#8201;10.30                                       |
| if             | sodium content per dosage unit (e.g., tablet, teaspoonful) if the sodium content of a single maximum recommended                                                 |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | &#167;&#167;&#8201;201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical            |
| if             | of OTC drug products intended for oral ingestion if the amount of sodium in the labeled maximum                                                                  |
| if             | of OTC drug products intended for oral ingestion if the amount of sodium in the labeled maximum                                                                  |
| if             | of OTC drug products intended for oral ingestion if the amount of sodium in the labeled maximum                                                                  |
| subject to     | (i) Any product  subject to this paragraph that contains sodium bicarbonate, sodium phosphate,                                                                   |
| subject to     | (j) Any product  subject to paragraphs (a) through (h) of this section that                                                                                      |
| subject to     | application for any single entity and combination products subject to drug marketing applications approved on or after April                                     |
| subject to     | Septemeber 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                            |
| subject to     | Septemeber 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                            |
| if             | shall contain the sodium content per delivered dose if  the sodium content is 5 milligrams or more.                                                              |
| if             | shall be rounded-off to the nearest whole number if expressed in milligrams (or nearest tenth of a                                                               |
| if             | shall be rounded-off to the nearest whole number if expressed in milligrams (or nearest tenth of a                                                               |
| subject to     | Any product  subject to this paragraph that contains dibasic sodium phosphate and/or                                                                             |
| unless         | format requirements in this section must be followed unless otherwise specifically provided in the applicable monograph or                                       |
| if             | 508 of the act (21 U.S.C. 358), or, if there is no designated official name and the                                                                              |
| if             | 508 of the act (21 U.S.C. 358), or, if there is no designated official name and the                                                                              |
| if             | the outside container of the retail package or, if there is no such outside container, all surfaces                                                              |
| if             | the retail package, or the immediate container label if there is no outside container or wrapper, shall                                                          |
| where          | the principal intended action(s) of the drug or, where the drug consists of more than one ingredient,                                                            |
| if             | followed by one or more of the following, if applicable: (i) &#8220;For external use only&#8221; [in bold                                                        |
| unless         | in which consumers should not use the product unless a prior diagnosis has been established by a                                                                 |
| if             | (iv) &#8220;Ask a doctor before use  if you have&#8221; [in bold type] or, for products                                                                          |
| if             | (iv) &#8220;Ask a doctor before use  if you have&#8221; [in bold type] or, for products                                                                          |
| until          | in which consumers should not use the product until  a doctor is consulted.                                                                                      |
| if             | (v) &#8220;Ask a doctor or pharmacist before use  if you are&#8221; [in bold type] or, for products                                                              |
| if             | (v) &#8220;Ask a doctor or pharmacist before use  if you are&#8221; [in bold type] or, for products                                                              |
| if             | (ii) The phenylalanine/aspartame content required by &#167;&#8201;201.21(b),  if applicable, shall appear as the next item of                                    |
| when           | of the week and times of the day when a person is available to respond to questions                                                                              |
| unless         | be presented in a single, alternative, contrasting color unless otherwise provided in an approved drug application, OTC                                          |
| when           | or solid circle bullet of 5-point type size. when                                                                                                                |
| if             | the retail package, or the immediate container label if  there is no outside container or wrapper.                                                               |
| when           | heading &#8220;Directions&#8221; shall appear in a table format when dosage directions are provided for three or more                                            |
| if             | this section, printed in accordance with the spec if ications in paragraphs (d)(1) through (d)(9) of this                                                        |
| if             | (d)(4) of this section shall apply except that if more than one bulleted statement is placed on                                                                  |
| if             | paragraph (d)(8) of this section may be omitted if the Drug Facts labeling is set off from                                                                       |
| when           | deleted from the labeling of OTC drug products when the labeling is revised to comply with this                                                                  |
| subject to     | format and content requirements in this section is subject to  regulatory action.                                                                                |
| if             | calcium content per dosage unit (e.g., tablet, teaspoonful) if the calcium content of a single maximum recommended                                               |
| if             | 5 milligrams (or nearest tenth of a gram if  over 1 gram).                                                                                                       |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | &#167;&#167;&#8201;201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical            |
| subject to     | (d) Any product  subject to this paragraph that is not labeled as required                                                                                       |
| subject to     | application for any single entity and combination products subject to drug marketing applications approved on or after April                                     |
| subject to     | September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                             |
| subject to     | September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                             |
| if             | magnesium content per dosage unit (e.g., tablet, teaspoonful) if the magnesium content of a single maximum recommended                                           |
| if             | 5 milligrams (or nearest tenth of a gram if  over 1 gram).                                                                                                       |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | &#167;&#167;&#8201;201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical            |
| subject to     | (d) Any product  subject to this paragraph that is not labeled as required                                                                                       |
| subject to     | application for any single entity and combination products subject to drug marketing applications approved on or after April                                     |
| subject to     | 2005, for all OTC drug products  subject to any OTC drug monograph, not yet the subject                                                                          |
| subject to     | 2005, for all OTC drug products  subject to any OTC drug monograph, not yet the subject                                                                          |
| if             | potassium content per dosage unit (e.g., tablet, teaspoonful) if the potassium content of a single maximum recommended                                           |
| if             | 5 milligrams (or nearest tenth of a gram if  over 1 gram).                                                                                                       |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | following statement under the heading &#8220;Warning&#8221; (or &#8220;Warnings&#8221; if  it appears with additional warning statements)                        |
| if             | &#167;&#167;&#8201;201.64(c), 201.70(c), 201.71(c), and 201.72(c) may be combined, if applicable, provided the ingredients are listed in alphabetical            |
| subject to     | (d) Any product  subject to this paragraph that is not labeled as required                                                                                       |
| subject to     | application for any single entity and combination products subject to drug marketing applications approved on or after April                                     |
| subject to     | September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                             |
| subject to     | September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject                                                             |
| if not         | Each section heading listed in &#167;&#8201;201.56(d),  if not omitted under &#167;&#8201;201.56(d)(3), shall contain the following information                  |
| if             | (i) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | (i) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | (i) The proprietary name and the established name, if any, as defined in section 502(e)(2) of the                                                                |
| if             | as physical constants, or pH, shall be stated. if                                                                                                                |
| if             | information based on in vitro and/or animal data if the information is essential to a description of                                                             |
| if             | and effective use of the drug is required, if known, e.g., degree and rate of absorption, pathways                                                               |
| if             | of action of the drug is unknown or if important metabolic or pharmacokinetic data in humans are                                                                 |
| if             | vitro data for anti-infective drugs may be included if the data are immediately preceded by the statement                                                        |
| if             | vitro data for anti-infective drugs may be included if the data are immediately preceded by the statement                                                        |
| if             | patients with vasomotor rhinitis; and/or (iv) The drug, if used for a particular indication only in conjuction                                                   |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless the requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)              |
| if not         | implied or suggested in other sections of labeling if not  included in this section.                                                                             |
| if not         | implied or suggested in other sections of labeling if not  included in this section.                                                                             |
| if             | state the limitations of usefulness of the drug. if                                                                                                              |
| if             | of improvement to be anticipated shall be stated if available and shall be based on substantial evidence                                                         |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless the requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)              |
| if             | this information shall be stated in this section. if                                                                                                             |
| if             | (iii) If there are spec if ic conditions that should be met before the                                                                                           |
| if             | (iii) If there are spec if ic conditions that should be met before the                                                                                           |
| if             | may be effective for a certain use or if there is a common use of the drug                                                                                       |
| if             | may be effective for a certain use or if there is a common use of the drug                                                                                       |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless this requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)             |
| if             | and not theoretical possibilities shall be listed, e.g., if hypersensitivity to the drug has not been demonstrated,                                              |
| if             | by them, and steps that should be taken if  they occur.                                                                                                          |
| as soon as     | labeling shall be revised to include a warning as soon as there is reasonable evidence of an association of                                                      |
| if             | A spec if ic warning relating to a use not provided                                                                                                              |
| if             | The frequency of these serious adverse reactions and,  if known, the approximate mortality and morbidity rates for                                               |
| unless         | reprinted in or accompanying the prescription drug labeling unless such Medication Guide is to be detached and                                                   |
| if             | animal or in vitro data may be used if  shown to be clinically relevant.                                                                                         |
| when           | Drug incompatibilities, i.e., drug interactions that may occur  when drugs are mixed in vitro, as in a                                                           |
| if             | have been performed to evaluate carcinogenic potential and, if  so, the species and results.                                                                     |
| if             | subsection of the labeling may be omitted only if the drug is not absorbed systemically and the                                                                  |
| if             | Under this heading the labeling shall ident if y one of the following categories that applies                                                                    |
| if             | Under this heading the labeling shall ident if y one of the following categories that applies                                                                    |
| if             | of drug) should be used during pregnancy only if clearly needed.&#8221; The labeling shall also contain a                                                        |
| if             | to the fetus due to (name of drug). if                                                                                                                           |
| if             | this drug should be used during pregnancy only if clearly needed.&#8221; If animal reproduction studies have shown                                               |
| if             | this drug should be used during pregnancy only if clearly needed.&#8221; If animal reproduction studies have shown                                               |
| when           | (name of drug) increases the risk of abnormalities when administered during the first (second, third, or all)                                                    |
| if             | that the possibility of fetal harm is remote, if  the drug is used during pregnancy.                                                                             |
| if             | of drug) should be used during pregnancy only if clearly needed.&#8221; The labeling shall also contain a                                                        |
| if             | have shown an adverse effect on the fetus, if there are no adequate and well-controlled studies in                                                               |
| if             | have shown an adverse effect on the fetus, if there are no adequate and well-controlled studies in                                                               |
| if             | have shown an adverse effect on the fetus, if there are no adequate and well-controlled studies in                                                               |
| when           | or other adverse effect) in (name(s) of species) when  given in doses (x) times the human dose.                                                                  |
| if             | of drug) should be used during pregnancy only if  the potential benefit just                                                                                     |
| when           | whether (name of drug) can cause fetal harm when administered to a pregnant woman or can affect                                                                  |
| if             | should be given to a pregnant woman only if clearly needed.&#8221; The labeling shall contain a description                                                      |
| if             | be acceptable despite its potential risks (for example, if  the drug is needed in a l                                                                            |
| if             | be acceptable despite its potential risks (for example, if  the drug is needed in a l                                                                            |
| when           | states: &#8220;(Name of drug) can cause fetal harm when  administered to a pregnant woman.                                                                       |
| if             | If this drug is used during pregnancy, or  if the patient becomes pregnant while taking this drug,                                                               |
| if             | If this drug is used during pregnancy, or  if the patient becomes pregnant while taking this drug,                                                               |
| if             | If this drug is used during pregnancy, or  if the patient becomes pregnant while taking this drug,                                                               |
| when           | &#8220;(Name of drug) may (can) cause fetal harm when  administered to a pregnant woman.                                                                         |
| if             | If this drug is used during pregnancy, or  if the patient becomes pregnant while taking this drug,                                                               |
| if             | use during pregnancy that is not required spec if ically by one of the pregnancy categories,                                                                     |
| if             | systemically, this subsection of the labeling shall contain, if known, information about excretion of the drug in                                                |
| if             | systemically, this subsection of the labeling shall contain, if known, information about excretion of the drug in                                                |
| if             | contain one of the following statements, as appropriate. if                                                                                                      |
| if             | drug is associated with serious adverse reactions or if the drug has a known tumorigenic potential, the                                                          |
| if             | drug is associated with serious adverse reactions or if the drug has a known tumorigenic potential, the                                                          |
| when           | the labeling shall state: &#8220;Caution should be exercised when (name of drug) is administered to a nursing                                                    |
| if             | contain one of the following statements, as appropriate. if                                                                                                      |
| if             | whether this drug is excreted in human milk. if                                                                                                                  |
| when           | excreted in human milk, caution should be exercised when (name of drug) is administered to a nursing                                                             |
| if             | (ii) If there is a spec if ic pediatric indication (i.e., an indication d                                                                                        |
| if             | the labeling should be discussed in more detail, if appropriate, under the &#8220;Clinical Pharmacology&#8221; or &#8220;Clinical Studies&#8221;                 |
| if             | (iii) If there are spec if ic statements on pediatric use of the drug                                                                                            |
| if             | (iii) If there are spec if ic statements on pediatric use of the drug                                                                                            |
| if             | the labeling shall be discussed in more detail, if appropriate, under the &#8220;Clinical Pharmacology&#8221; or the &#8220;Clinical                             |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard shall be described in                                                               |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard shall be described in                                                               |
| if             | this pediatric population is associated with a spec if ic hazard, the hazard shall be described in                                                               |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard shall be described in                                                              |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard shall be described in                                                              |
| if             | other pediatric subgroups, is associated with a spec if ic hazard, the hazard shall be described in                                                              |
| if             | of the statements and may propose alternative statement(s). if                                                                                                   |
| if             | FDA may permit use of an alternative statement  if FDA determines that no statement described in those                                                           |
| if             | generally in the &#8220;Contraindications,&#8221; &#8220;Warnings,&#8221; or &#8220;Precautions&#8221; section. if                                               |
| if             | (i) A spec if ic geriatric indication,                                                                                                                           |
| if             | the labeling shall be discussed in more detail, if appropriate, under &#8220;Clinical Pharmacology&#8221; or the &#8220;Clinical Studies&#8221;                  |
| if             | over to determine whether elderly subjects respond d if ferently from younger subjects, and other reported clinical                                              |
| if             | elderly subjects to make it likely that d if ferences in safety or effectiveness between elderly and                                                             |
| if             | drug in elderly patients is associated with d if ferences in safety or effectiveness, or requires spec                                                           |
| if             | (iii)(A) If spec if ic pharmacokinetic or pharmacodynamic studies have been carried                                                                              |
| if             | the &#8220;Geriatric use&#8221; subsection shall include the statement: if                                                                                       |
| if             | in the elderly appears to cause a spec if ic hazard, the hazard shall be described in                                                                            |
| if             | in the elderly appears to cause a spec if ic hazard, the hazard shall be described in                                                                            |
| if             | through (f)(10)(iii) of this section may include statements, if they would be useful in enhancing safe use                                                       |
| if             | the statements and may propose an alternative statement. if                                                                                                      |
| if             | FDA may permit omission of the statements  if FDA determines that no statement described in those                                                                |
| if             | FDA may permit use of an alternative statement  if the agency determines that such statement is accurate                                                         |
| if             | the same pharmacologically active and chemically related class, if  applicable.                                                                                  |
| unless         | reactions).&#8221; Percent figures may not ordinarily be used unless they are documented by adequate and well-controlled studies                                 |
| if             | (3) The &#8220;Warnings&#8221; section of the labeling or,  if appropriate, the &#8220;Contraindications&#8221; section of the labeling shall                    |
| unless         | studies as defined in &#167;&#8201;314.126(b) of this chapter unless this requirement is waived under &#167;&#8201;201.58 or &#167;&#8201;314.126(c)             |
| when           | This section shall be based on human data,  when  available.                                                                                                     |
| if             | &#8220;Clinical Pharmacology&#8221; section also may be referenced here, if  applicable to overdoses.                                                            |
| unless         | system stimulants, respiratory stimulants) may not be stated unless specific data or scientific rationale exists to support                                      |
| if             | recommended usual dose, the usual dosage range, and, if appropriate, an upper limit beyond which safety and                                                      |
| when           | established; dosages shall be stated for each indication when  appropriate.                                                                                      |
| if not         | implied or suggested in other sections of labeling if not  included in this section.                                                                             |
| when           | (including the strength of the final dosage solution, when prepared according to instructions, in terms of milligrams                                            |
| unless         | milligrams active ingredient per milliliter of reconstituted solution, unless another measure of the strength is more appropriate),                              |
| if             | This section shall also contain spec if ic direction on dilution, preparation (including the strength                                                            |
| when           | (including the strength of the final dosage solution, when prepared according to instructions, in terms of milligrams                                            |
| if             | This section shall also contain spec if ic direction on dilution, preparation (including the strength                                                            |
| if             | form, e.g., 10-milligram tablets, in metric system and, if the apothecary system is used, a statement of                                                         |
| if             | A reference to a spec if ic important clinical study may be made in                                                                                              |
| if             | &#8220;Indications and Usage&#8221; or &#8220;Dosage and Administration&#8221; section. if                                                                       |
| when           | a reference to the source of the information. when                                                                                                               |
| if             | the risk or risks shall also be ident if ied or discussed in the appropriate section of                                                                          |
| subject to     | A drug  subject to the requirements of section 503(b)(1) of the act                                                                                              |
| if             | the act shall be exempt from section 502(f)(1) if all the following conditions are met: (a) The                                                                  |
| if             | the act shall be exempt from section 502(f)(1) if all the following conditions are met: (a) The                                                                  |
| if             | the act shall be exempt from section 502(f)(1) if all the following conditions are met: (a) The                                                                  |
| unless         | designated as coloring without naming specific color components unless the naming of such components is required by                                              |
| if             | name and a statement of their effect; and if the vehicle is water for injection it need                                                                          |
| if             | or required as a condition for the cert if ication or the exemption from cert                                                                                    |
| subject to     | or represented; and (2) If the article is subject to section 505 of the act, the labeling bearing                                                                |
| if             | for which it is advertised or represented; and if the article is subject to section 505 of                                                                       |
| subject to     | advertised or represented; and if the article is subject to section 505 of the act, the parts of                                                                 |
| if             | only the proprietary name of the drug product, if  any; the established name of the drug product,                                                                |
| if             | only the proprietary name of the drug product, if  any; the established name of the drug product,                                                                |
| subject to     | price information including, but not limited to, those subject to the requirements of &#167;&#8201;200.200 of this chapter, is                                   |
| subject to     | Reminder labeling, other than that  subject to the requirements of &#167;&#8201;200.200 of this chapter, is                                                      |
| if             | the manufacturer, packer, or distributor will be not if ied either in the publication of the conclusions                                                         |
| subject to     | Reminder labeling, other than that  subject to the requirements of &#167;&#8201;200.200 of this chapter, is                                                      |
| subject to     | A drug  subject to the requirements of section 503(f)(1) of the act                                                                                              |
| if             | be exempt from section 502(f)(1) of the act if all the following conditions are met: (a) The                                                                     |
| if             | usual dosage; and (3) The route of administration, if it is not for oral use; and (4)                                                                            |
| if             | usual dosage; and (3) The route of administration, if it is not for oral use; and (4)                                                                            |
| unless         | designated as coloring without naming specific color components unless the naming of such components is required by                                              |
| if             | section may be omitted from the dispensing package if , but only                                                                                                 |
| subject to     | (2) If the article is  subject to section 512 or 572 of the act, the                                                                                             |
| if             | section may be omitted from the dispensing package if , but only                                                                                                 |
| if             | section may be omitted from the dispensing package if , but only                                                                                                 |
| if             | for which it is advertised or represented; and if the article is subject to section 512 or                                                                       |
| subject to     | advertised or represented; and if the article is subject to section 512 or 572 of the act, the                                                                   |
| if             | or 572(g) of the act and regulations thereunder. if                                                                                                              |
| unless         | results in the preparation of a new drug, unless  an approved new-drug application provides for such use.                                                        |
| subject to     | devices, and may also be a biological product subject to  section 351 of the Public Health Service Act.                                                          |
| if             | this section and section 502(f)(1) of the act if it meets the requirements of &#167;&#8201;809.10 of this                                                        |
| if             | be exempt from section 502(f)(1) of the act if all the following conditions are met: (a) The                                                                     |
| if             | be exempt from section 502(f)(1) of the act if all the following conditions are met: (a) The                                                                     |
| subject to     | in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement &#8220;Rx                                                              |
| if             | the conditions for which it is so sold. if                                                                                                                       |
| not subject to | (3) If it is  not subject to section 503(b)(1) of the act and is by                                                                                              |
| unless         | in compounding which results in a new drug, unless an approved new-drug application covers such use of                                                           |
| if             | be exempt from section 502(f)(1) of the act if its label bears the statement &#8220;Caution: For manufacturing,                                                  |
| if             | be exempt from section 502(f)(1) of the act if its label bears the statement &#8220;Caution: For manufacturing,                                                  |
| subject to     | in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement &#8220;Rx                                                              |
| if             | be exempt from section 502(f)(1) of the act if its label bears the statement &#8220;Caution: For manufacturing,                                                  |
| subject to     | in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement &#8220;Rx                                                              |
| if             | request for addition to the index is granted. if                                                                                                                 |
| until          | is not further distributed after it is manufactured until after the new drug application or new animal                                                           |
| subject to     | A drug  subject to &#167;&#8201;201.100 or &#167;&#8201;201.105, shall be exempt from section                                                                    |
| if             | be exempt from section 502(f)(1) of the act if shipped or sold to, or in the possession                                                                          |
| if             | made for any purpose other than those spec if ied, such exemption shall expire, with respect to                                                                  |
| unless         | act which results in such drug being misbranded unless it is disposed of under circumstances in which                                                            |
| until          | &#167;&#167;&#8201;201.117, 201.119, 201.120, 201.122, and 201.125 shall continue until the drugs are used for the purposes for                                  |
| until          | &#167;&#167;&#8201;201.117, 201.119, 201.120, 201.122, and 201.125 shall continue until the drugs are used for the purposes for                                  |
| unless         | no exemption shall thereafter apply to the article unless the dosage form is labeled as required by                                                              |
| if             | And  if the totality of the evidence establishes that a                                                                                                          |
| if             | But  if a manufacturer knows, or has knowledge of facts                                                                                                          |
| if             | be exempt from section 502(f)(1) of the act if the packaging, label, and labeling are in compliance                                                              |
| where          | substantial quantity at an establishment other than that where originally processed or packed, shall be exempt, during                                           |
| where          | substantial quantity at an establishment other than that where originally processed or packed, shall be exempt, during                                           |
| if             | (d), (e), (f), and (g) of the act if : (1) The person who introduced such shipment                                                                               |
| until          | shall each keep a copy of such agreement until 2 years after the final shipment or delivery                                                                      |
| if             | thereof, from such establishment, become void ab initio if the drug comprising such shipment, delivery, or part                                                  |
| when           | or misbranded within the meaning of the act when  so removed.                                                                                                    |
| if             | delivery, or any part thereof, from such establishment if the drug comprising such shipment, delivery, or part                                                   |
| when           | or misbranded within the meaning of the act when so removed; or (2) Upon refusal by the                                                                          |
| where          | Upon refusal by the operator of the establishment where such drug is to be processed, labeled, or                                                                |
| provided that  | the requirements of &#167;&#8201;201.100(b)(2) and (3), and (c)(1), provided that , where applicable, the requirements of &#167;&#167;&#8201;201.328 and         |
| where          | of &#167;&#8201;201.100(b)(2) and (3), and (c)(1), provided that, where applicable, the requirements of &#167;&#167;&#8201;201.328 and 211.94(e)(2) of           |
| unless         | be used on patients who have stopped breathing unless used in conjunction with resuscitative equipment; and, in                                                  |
| when           | oxygen deficiency or for use in emergency resuscitation when administered by properly trained personnel, a warning statement                                     |
| when           | oxygen deficiency or for use in emergency resuscitation when administered by properly trained personnel, a warning statement                                     |
| unless         | Efficacy Study Implementation notice on a prescription drug, unless exempted or otherwise provided for in the notice,                                            |
| unless         | Efficacy Study Implementation notice on a prescription drug, unless exempted or otherwise provided for in the notice,                                            |
| if             | be safely and effectively used, an appropriate qual if ication of all claims evaluated as other than                                                             |
| if             | However, this qual if ying information will be required in advertisements only                                                                                   |
| if             | However, this qual if ying information will be required in advertisements only                                                                                   |
| as soon as     | and such labeling shall be put into use as soon as possible but not later than the end of                                                                        |
| where          | On each page  where less-than-effective indication(s) appear in a mutiple page advertisement,                                                                    |
| if             | the most prominent mention of the indi- cation(s); if the degree of prominence does not vary, an                                                                 |
| if             | Information,&#8221; the latter legend to be used only if the advertisement carries the required information for professional                                     |
| when           | of &#167;&#8201;201.100 permitting omission of directions for use when  the label bears the prescription legend.                                                 |
| if             | such articles will be considered to be misbranded if  they are distributed for use as drugs.                                                                     |
| subject to     | inert glandular materials for parenteral use are therefore subject to the same comment as applies to those intended                                              |
| when           | activity of such nonhydroxyketonic estrogenic hormones and estrone, when  measured by different methods on test animals.                                         |
| when           | These studies have indicated that  when mineral oil is used orally near mealtime it                                                                              |
| when           | mistakenly regarded by the public as harmless even when  taken in substantially larger amounts.                                                                  |
| when           | Actually, it is quite toxic  when  taken in quantities of a teaspoonful or more.                                                                                 |
| when           | odor and are likely to swallow these products when  left within reach.                                                                                           |
| when           | causing diminished liver function and severe liver necrosis when  absorbed in sufficient amounts.                                                                |
| if             | There is a lack of scient if ic evidence to establish the conditions,                                                                                            |
| when           | (b) In view of the hazards involved  when tannic acid is used in barium enemas, any                                                                              |
| unless         | of the Federal Food, Drug, and Cosmetic Act unless the label and the labeling bear conspicuously a                                                               |
| until          | not responded completely to other forms of therapy until  use of the isoproterenol inhalation preparation was discontinued.                                      |
| if             | The mechanism of these deaths and their relationship,  if any, to the cases of severe paradoxical bronchospasm                                                   |
| if             | marketing of isoproterenol inhalation preparations may be continued if  all the following conditions are met:                                                    |
| unless         | per milliliter, labeled or intended for human use, unless all the following conditions are met: (1) The                                                          |
| when           | use containing sodium phosphates as an active ingredient when marketed as described in paragraph (a) of this                                                     |
| unless         | of the Federal Food, Drug, and Cosmetic Act unless packaged and labeled as follows: (1) Package size                                                             |
| unless         | dosage information: &#8220;Do not&#8221; (&#8220;take&#8221; or &#8220;use&#8221;) &#8220;more unless  directed by a doctor.                                     |
| subject to     | is not in compliance with this section is subject to  regulatory action.                                                                                         |
| provided that  | syrup to be available for sale without prescription, provided that it is packaged in a quantity of 1                                                             |
| if             | Ordinarily, this drug should not be used  if strychnine, corrosives such as alkalies (lye) and strong                                                            |
| when           | following effect: &#8220;Warning&#8212;This medication may damage the kidneys when used in large amounts or for a long                                           |
| unless         | of the Federal Food, Drug, and Cosmetic Act, unless the label and labeling on or within the                                                                      |
| if             | Use of the drug should be discontinued  if  leukopenia occurs or                                                                                                 |
| if             | Use of the drug should be discontinued  if  leukopenia occurs or                                                                                                 |
| unless         | the act on or after November 25, 1961, unless such preparations are labeled in accordance with paragraph                                                         |
| if             | article as simply &#8220;Estradiol&#8221;; nor would it object if the label of a preparation containing this substance                                           |
| if             | of children [highlighted in bold type],&#8221; except that if the article is an aspirin preparation, it shall                                                    |
| if             | 3 years of age consult your physician.&#8221; However, if the directions provide for administration to children only                                             |
| if             | and pains of arthritis and rheumatism.&#8221; The qual if ying phrase &#8220;for the temporary relief of minor                                                   |
| if             | period or 10 grains in a 4-hour period. if                                                                                                                       |
| if             | bear a caution such as, &#8220;Caution: Discontinue use if  excessive irritation of the skin develops.                                                           |
| if             | bear a caution such as, &#8220;Caution: Discontinue use if  excessive irritation of the skin develops.                                                           |
| subject to     | containing aspirin or nonaspirin salicylates as active ingredients subject to this paragraph is required to prominently bear the                                 |
| if             | When using this product,  if changes in behavior with nausea and vomiting occur,                                                                                 |
| where          | In cases  where the immediate container is not the retail package,                                                                                               |
| subject to     | under the heading &#8220;Warnings.&#8221; (3) Over-the-counter drug products subject to this paragraph and labeled solely for use by                             |
| subject to     | (4) Any product  subject to paragraphs (h)(1), (h)(2), and (h)(3) of this section                                                                                |
| when           | or for menstrual drug products) will be established when the final monographs for those products are published                                                   |
| unless         | administer to children under 3 years of age unless directed by physician.&#8221; Drugs with thyroid hormone activity                                             |
| unless         | of the Federal Food, Drug, and Cosmetic Act unless their labeling bears the following boxed warning at                                                           |
| unless         | of the Federal Food, Drug, and Cosmetic Act unless their labeling bears the following boxed warning at                                                           |
| when           | mucilloids as active ingredients are significant health risks when  these products are taken without adequate fluid or                                           |
| when           | mucilloids as active ingredients are significant health risks when  these products are taken without adequate fluid or                                           |
| when           | gum, or hydrophilic mucilloid as an active ingredient when marketed in a dry or incompletely hydrated form                                                       |
| when           | an active ingredient in an oral dosage form when marketed in a dry or incompletely hydrated form                                                                 |
| unless         | of the Federal Food, Drug, and Cosmetic Act unless their labeling bears the following warnings (under the                                                        |
| if             | Do not take this product  if  you have d                                                                                                                         |
| subject to     | is not in compliance with this section is subject to  regulatory action.                                                                                         |
| if             | handling and storage conditions on the physician labeling: if                                                                                                    |
| until          | or (3) The maximum historical level, but only until completion of production of the first five batches                                                           |
| if             | aluminum will be no more than 25 &#181;g/L&#8221;. if                                                                                                            |
| if             | aluminum will be no more than 25 &#181;g/L&#8221;. if                                                                                                            |
| not subject to | Manufacturers of parenteral drug products  not subject to an approved application must make assay methodology available                                          |
| when           | vaginal epithelium, and also can cause epithelial disruption when  used in the rectum.                                                                           |
| subject to     | containing nonoxynol 9 as the active ingredient, whether subject to the ongoing OTC drug review or an approved                                                   |
| if             | (3) &#8220;Do not use&#8221; [in bold type]  if  you or your sex partner has HIV/AIDS.                                                                           |
| if             | If you do not know  if you or your sex partner is infected, choose                                                                                               |
| if             | (5) &#8220;Stop use and ask a doctor  if [in bold type] [optional, bullet] you or your                                                                           |
| when           | Drug Facts labeling in accordance with &#167;&#8201;201.66(c)(7), &#8220;[bullet] when used correctly every time you have sex, latex                             |
| if             | control with or without a diaphragm or condom if you have sex with only one partner who                                                                          |
| if             | &#8220;[bullet] use a latex condom without nonoxynol 9 if you or your sex partner has HIV/AIDS, multiple                                                         |
| if             | (4) &#8220;[bullet] ask a health professional  if you have questions about your best birth control                                                               |
| subject to     | (e) Any drug product  subject to this section that is not labeled as required                                                                                    |
| subject to     | (e) Any drug product  subject to this section that is not labeled as required                                                                                    |
| if             | Severe liver damage may occur  if you take [bullet] more than [insert maximum number                                                                             |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | or pharmacist.&#8221; (C) &#8220;Ask a doctor before use if  you have liver disease&#8221;.                                                                      |
| if             | (D) &#8220;Ask a doctor or pharmacist before use  if you are taking the blood thinning drug warfarin&#8221;                                                      |
| if             | Severe liver damage may occur  if your child takes [bullet] more than 5 doses                                                                                    |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | or pharmacist.&#8221; (3) &#8220;Ask a doctor before use if  your child has liver disease&#8221;.                                                                |
| if             | (4) &#8220;Ask a doctor or pharmacist before use  if your child is taking the blood thinning drug                                                                |
| if             | Severe liver damage may occur  if [bullet] adult takes more than [insert maximum number                                                                          |
| if             | Severe liver damage may occur  if [bullet] adult takes more than [insert maximum number                                                                          |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | (B) &#8220;Ask a doctor before use  if the user has liver disease.&#8221; (C) &#8220;Do not                                                                      |
| if             | (D) &#8220;Ask a doctor or pharmacist before use if the user is taking the blood thinning drug                                                                   |
| if             | The chance is higher  if you [bullet] are age 60 or older [bullet]                                                                                               |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | (B) &#8220;Ask a doctor before use  if [bullet] stomach bleeding warning applies to you [bullet]                                                                 |
| if             | (C) &#8220;Stop use and ask a doctor  if [bullet] you experience any of the following signs                                                                      |
| if             | The chance is higher  if your child [bullet] has had stomach ulcers or                                                                                           |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | (2) &#8220;Ask a doctor before use  if [bullet] stomach bleeding warning applies to your child                                                                   |
| if             | (3) &#8220;Stop use and ask a doctor  if [bullet] child experiences any of the following signs                                                                   |
| if             | The chance is higher  if the user [bullet] has had stomach ulcers or                                                                                             |
| when           | the blister card and remain intact and readable when  drug product is removed from the blister card.                                                             |
| if             | The labeling states &#8220;Ask a doctor before use if [bullet] stomach bleeding warning applies to user [bullet]                                                 |
| if             | labeling states &#8220;Stop use and ask a doctor if [bullet] user experiences any of the following signs                                                         |
| subject to     | The labeling of any drug product  subject to this section that is initially introduced or initially                                                              |
| subject to     | that contain internal analgesic/antipyretic active ingredients that are subject to the requirements of paragraph (a) of this section                             |
| if             | product contains the established name of the drug, if  any, and ident                                                                                            |
| subject to     | used, as provided in &#167;&#8201;330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal                                           |
| if             | in addition to the indication in &#167;&#8201;201.327(c)(1): &#8220;[Bullet] if used as directed with other sun protection measures                              |
| if             | labeling states &#8220;Stop use and ask a doctor if  [bullet] rash occurs&#8221;.                                                                                |
| if             | 2 hours [bullet] use a water resistant sunscreen if  swimming or sweating&#8221;.                                                                                |
| if             | In addition, the solar simulator must be recalibrated  if there is any change in the lamp bulb                                                                   |
| until          | obtained for the original calibrated lamp will suffice until measurements can be performed with the spectroradiometer at                                         |
| until          | Mix at 77 to 82 &#176;C  until  uniform.                                                                                                                         |
| until          | the remaining ingredients of Part B and mix until  uniform.                                                                                                      |
| until          | 2 and mix at 77 to 82 &#176;C until  smooth and uniform.                                                                                                         |
| until          | Step 3 at 49 to 54 &#176;C. Mix until  uniform.                                                                                                                  |
| until          | Mix  until  uniform.                                                                                                                                             |
| until          | 30 mL of isopropanol and heat with swirling until  contents are evenly dispersed.                                                                                |
| if             | of nevi, blemishes, or moles will be acceptable if , in the physician's judgment, they will neither                                                              |
| if             | Excess hair on the back is acceptable  if  the hair is clipped.                                                                                                  |
| where          | shoulder blades (scapulae) and lateral to the midline, where  skin responses to UV radiation are determined.                                                     |
| until          | shield the exposed area from further UV radiation until  the MED is determined.                                                                                  |
| when           | subject should be in the same position as when  the test site was irradiated.                                                                                    |
| if             | Reject test data for a test subject  if erythema is not present on either the unprotected                                                                        |
| until          | the exposed testing sites from further UV radiation until  the MED is determined).                                                                               |
| if             | gas designated in paragraph (c) of this section. if                                                                                                              |
| if             | colors designated in paragraph (c) of this section if the gas or gases held within the container                                                                 |
| when           | The color or colors must be visible  when  viewed from the top of cylinder.                                                                                      |


## Entities

| Entities                   | Context                                                                                                                                                                            |
|:---------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                                                                                   |
| Drugs                      | Drugs ; name and place of business of manufacturer,                                                                                                                                |
| Certain                    | by stating on the product label that &#8220; Certain manufacturing operations have been performed by other firms.&#8221;;                                                          |
| Incorporated               | &#8220;Company,&#8221; &#8220; Incorporated ,&#8221; etc., may be abbreviated or omitted and                                                                                       |
| Paragraphs                 | (k)  Paragraphs (b), (c), (d), (e), and (f) of this                                                                                                                                |
| Drugs                      | Drugs ; adequate directions for use.                                                                                                                                               |
| Adequate                   | Adequate directions for use means directions under which the                                                                                                                       |
| Drugs                      | Drugs ; misleading statements.                                                                                                                                                     |
| Drugs                      | Drugs ; statement of ingredients.                                                                                                                                                  |
| Drugs                      | Drugs ; prominence of required label statements.                                                                                                                                   |
| English                    | label or labeling shall appear thereon in the English language: Provided, however, That in the case of                                                                             |
| Puerto Rico                | of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language                                                                 |
| English                    | label or labeling shall appear thereon in the English language: Provided, however, That in the case of                                                                             |
| English                    | label or labeling shall appear thereon in the English language: Provided, however, That in the case of                                                                             |
| Drugs                      | Drugs ; Spanish-language version of certain required statements.                                                                                                                   |
| Spanish                    | prescription use only are being labeled solely in Spanish for distribution in the Commonwealth of Puerto Rico                                                                      |
| Puerto Rico                | in Spanish for distribution in the Commonwealth of Puerto Rico  where Spanish is the predominant language.                                                                         |
| Spanish                    | prescription use only are being labeled solely in Spanish for distribution in the Commonwealth of Puerto Rico                                                                      |
| Such                       | Such  labeling is authorized under &#167;&#8201;201.15(c).                                                                                                                         |
| English                    | of which is fixed by law in the English language, could be translated in various ways, from                                                                                        |
| Drugs                      | Drugs ; location of expiration date.                                                                                                                                               |
| Drugs                      | Drugs ; significance of control numbers.                                                                                                                                           |
| Drugs                      | Drugs ; use of term “infant”.                                                                                                                                                      |
| Phenylalanine              | a statement to the following effect: Phenylketonurics: Contains Phenylalanine  (_)mg Per (Dosage Unit).                                                                            |
| Phenylalanine              | the labeling, as required in &#167;&#8201;201.57(f)(2): Phenylketonurics: Contains Phenylalanine  (_)mg Per (Dosage Unit).                                                         |
| Contains                   | emergency situations, shall bear the warning statement &#8220; Contains (insert the name of the sulfite, e.g., sodium                                                              |
| Sulfite                    | Sulfite sensitivity is seen more frequently in asthmatic than                                                                                                                      |
| Epinephrine                | emergency situations shall bear the warning statement &#8220; Epinephrine is the preferred treatment for serious allergic or                                                       |
| Indications                | (b) In the &#8220; Indications  and Usage&#8221; section, the labeling must state:                                                                                                 |
| Bar                        | Bar  code label requirements.                                                                                                                                                      |
| Remain                     | bar code can be scanned correctly; and (ii) Remain  intact under normal conditions of use.                                                                                         |
| Research                   | Office of Compliance, Center for Drug Evaluation and Research , Food and Drug Administration, 10903 New Hampshire                                                                  |
| Research                   | regulated by the Center for Drug Evaluation and Research ) or to the Food and Drug Administration,                                                                                 |
| Rm                         | 71,  Rm .                                                                                                                                                                          |
| G112                       | G112 , Silver Spring, MD 20993-0002 (requests involving a                                                                                                                          |
| Explain                    | subject of the exception or alternative request; (iii) Explain why compliance with such labeling provision(s) could adversely                                                      |
| U.S                        | prescription drugs be expressed in terms of the U.S . gallon of 231 cubic inches and quart,                                                                                        |
| U.S. Pharmacopeia          | volume prescribed by the National Formulary or the U.S. Pharmacopeia  for filling of ampules.                                                                                      |
| U.S. Pharmacopeia          | shall comply with the limitations provided in the U.S. Pharmacopeia  or the National Formulary.                                                                                    |
| Highlights                 | (3) Any reference in  Highlights to information appearing in the full prescribing information                                                                                      |
| Specific Populations       | the &#8220;Contraindications,&#8221; &#8220;Warnings and Precautions,&#8221; or &#8220;Use in Specific Populations &#8221; section of labeling.                                    |
| Highlights                 | section must be listed under this heading in Highlights for at least 1 year after the date                                                                                         |
| Highlights                 | class, the concise statement under this heading in Highlights must identify the class in the following manner:                                                                     |
| Adverse                    | Adverse reactions important for other reasons (e.g., because they                                                                                                                  |
| Highlights                 | must not be repeated under this heading in Highlights  if they are included elsewhere in                                                                                           |
| Contraindications          | included elsewhere in Highlights (e.g., Warnings and Precautions, Contraindications ).                                                                                             |
| Highlights                 | identified as such, placed at the end of Highlights .                                                                                                                              |
| Certain                    | Certain contraindications or serious warnings, particularly those that may                                                                                                         |
| Information                | Information on therapeutic drug concentration monitoring (TDM) must also                                                                                                           |
| Indications                | a use not provided for under the &#8220; Indications and Usage&#8221; section may be required by FDA                                                                               |
| United States              | the percentage range of live births in the United States with a major birth defect and the percentage                                                                              |
| United States              | the percentage range of live births in the United States with a major birth defect and the percentage                                                                              |
| Data                       | Under the subheading &#8220; Data ,&#8221; the labeling must describe the data that                                                                                                |
| Animal                     | Animal doses or exposures must be described in terms                                                                                                                               |
| Data                       | Under the subheading &#8220; Data ,&#8221; the labeling must describe the data that                                                                                                |
| Infertility                | under the subheadings &#8220;Pregnancy Testing,&#8221; &#8220;Contraception,&#8221; and &#8220; Infertility ,&#8221; in that order.                                                |
| Indications                | population, it must be described under the &#8220; Indications and Usage&#8221; section, and appropriate pediatric dosage information                                              |
| Appropriate                | Appropriate pediatric dosage must be given under the &#8220;Dosage                                                                                                                 |
| Pediatric                  | Pediatric dosing instructions must be included in the &#8220;Dosage                                                                                                                |
| Geriatric                  | (v) 8.5  Geriatric  use.                                                                                                                                                           |
| Indications                | geriatric population must be described under the &#8220; Indications and Usage&#8221; section, and appropriate geriatric dosage must                                               |
| Geriatric                  | The &#8220; Geriatric use&#8221; subsection must cite any limitations on the                                                                                                       |
| Geriatric                  | Unless otherwise noted, information contained in the &#8220; Geriatric use&#8221; subsection must pertain to use of the                                                            |
| Geriatric                  | geriatric indication, must be contained in the &#8220; Geriatric use&#8221; subsection and must reflect all information available                                                  |
| Geriatric                  | The &#8220; Geriatric use&#8221; subsection must contain the following statement(s) or                                                                                             |
| Geriatric                  | The &#8220; Geriatric use&#8221; subsection must contain the following statement(s) or                                                                                             |
| Geriatric                  | experience has not identified such differences, the &#8220; Geriatric use&#8221; subsection must contain the following statement: (3)                                              |
| Geriatric                  | experience has not identified such differences, the &#8220; Geriatric use&#8221; subsection must contain the following statement: (3)                                              |
| Geriatric                  | they must be described briefly in the &#8220; Geriatric use&#8221; subsection and in detail under the &#8220;Clinical                                                              |
| Geriatric                  | be substantially excreted by the kidney, the &#8220; Geriatric use&#8221; subsection must include the statement: (D) If                                                            |
| Geriatric                  | be substantially excreted by the kidney, the &#8220; Geriatric use&#8221; subsection must include the statement: (D) If                                                            |
| Geriatric                  | be substantially excreted by the kidney, the &#8220; Geriatric use&#8221; subsection must include the statement: (D) If                                                            |
| Pharmacologic              | Pharmacologic information based on in vitro data using human                                                                                                                       |
| Detailed                   | Detailed dosing or monitoring recommendations based on pharmacodynamic information                                                                                                 |
| Specific Populations       | and Precautions,&#8221; &#8220;Dosage and Administration&#8221; or &#8220;Use in Specific Populations &#8221;) must not be repeated in this subsection,                            |
| Human                      | Human data suggesting that the drug may be carcinogenic                                                                                                                            |
| Significant                | Significant animal data necessary for safe and effective use                                                                                                                       |
| Indications                | or dosing regimens not stated in the &#8220; Indications  and Usage&#8221; or &#8220;Dosage and Administration&#8221; section.                                                     |
| Indications                | or dosing regimens not stated in the &#8220; Indications  and Usage&#8221; or &#8220;Dosage and Administration&#8221; section.                                                     |
| Reverse                    | Reverse type is not permitted as a form of                                                                                                                                         |
| Research                   | the Director's designee), Center for Drug Evaluation and Research , Food and Drug Administration, Central Document Room,                                                           |
| Beltsville, MD             | Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, or, if applicable, the Director (or the                                               |
| Research                   | the Director's designee), Center for Drug Evaluation and Research , Food and Drug Administration, Central Document Room,                                                           |
| Rm                         | 71,  Rm .                                                                                                                                                                          |
| G112                       | G112 , Silver Spring, MD 20993-0002.                                                                                                                                               |
| Principal                  | Principal  display panel.                                                                                                                                                          |
| Such                       | Such term shall be augmented when necessary for accuracy                                                                                                                           |
| U.S                        | contents shall be expressed in terms of the U.S . gallon of 231 cubic inches and quart,                                                                                            |
| Rockville, MD              | 1061,  Rockville, MD  20852.                                                                                                                                                       |
| Sodium                     | Sodium  labeling.                                                                                                                                                                  |
| Format                     | Format and content requirements for over-the-counter (OTC) drug product                                                                                                            |
| Active                     | (2) &#8220; Active  ingredient&#8221; or &#8220;                                                                                                                                   |
| Allergic                   | Allergic reaction warnings set forth in any applicable OTC                                                                                                                         |
| Allergy                    | This warning shall follow the subheading &#8220; Allergy alert:&#8221; The asthma alert warning set forth in                                                                       |
| Asthma                     | This warning shall follow the subheading &#8220; Asthma  alert:&#8221;                                                                                                             |
| Sore                       | shall follow the subheading &#8220;Stomach bleeding warning:&#8221; (F) Sore  throat warning set forth in &#167;&#8201;201.315.                                                    |
| Sore                       | This warning shall follow the subheading &#8220; Sore throat warning:&#8221; (G) Warning for drug products containing                                                              |
| Dosage                     | This warning shall follow the subheading &#8220; Dosage warning:&#8221; (H) Sexually transmitted diseases (STDs) warning for                                                       |
| Additional                 | Additional bulleted statements appearing on each subsequent horizontal line                                                                                                        |
| Hyphens                    | Hyphens shall not be used except to punctuate compound                                                                                                                             |
| Use                        | the indications for use listed under the &#8220; Use (s)&#8221; heading, as set forth in paragraph (c)(4)                                                                          |
| Paragraphs                 | (i)  Paragraphs (d)(1), (d)(5), (d)(6), and (d)(7) of this section                                                                                                                 |
| Paragraph                  | (ii)  Paragraph (d)(2) of this section shall apply except that                                                                                                                     |
| Paragraph                  | (iii)  Paragraph (d)(3) of this section shall apply except that                                                                                                                    |
| Paragraph                  | (iv)  Paragraph (d)(4) of this section shall apply except that                                                                                                                     |
| Paragraph                  | (v)  Paragraph (d)(8) of this section shall apply except that                                                                                                                      |
| Rockville, MD              | 1061,  Rockville, MD  20852.                                                                                                                                                       |
| Request                    | clearly identified on the envelope as a &#8220; Request for Exemption from 21 CFR 201.66 (OTC Labeling                                                                             |
| Exemption                  | Exemption and deferral requests shall: (1) Document why a                                                                                                                          |
| Calcium                    | Calcium  labeling.                                                                                                                                                                 |
| Magnesium                  | Magnesium  labeling.                                                                                                                                                               |
| Potassium                  | Potassium  labeling.                                                                                                                                                               |
| Pharmacokinetic            | Pharmacokinetic information that is important to safe and effective                                                                                                                |
| Information                | Information on the approximate kind, degree, and duration of                                                                                                                       |
| Indications                | a use not provided for under the &#8220; Indications and Usage&#8221; section of the labeling may be                                                                               |
| Drug                       | Drug interactions supported only by animal or in vitro                                                                                                                             |
| Drug                       | Drug incompatibilities, i.e., drug interactions that may occur when                                                                                                                |
| Animal                     | studies in humans, the labeling shall state: &#8220; Animal reproduction studies have not been conducted with (name                                                                |
| Indications                | population, it shall be described under the &#8220; Indications and Usage&#8221; section of the labeling, and appropriate                                                          |
| Warnings                   | shall also be contained in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; and elsewhere in the &#8220;Precautions&#8221; sections.                                 |
| Appropriate                | Appropriate pediatric dosage shall be given under the &#8220;Dosage                                                                                                                |
| Warnings                   | shall also be contained in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; and elsewhere in the &#8220;Precautions&#8221; sections.                                 |
| Pediatric                  | Pediatric dosing instructions shall be included in the &#8220;Dosage                                                                                                               |
| Warnings                   | subsection and, as appropriate, in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; &#8220;Precautions,&#8221; and &#8220;Dosage and Administration&#8221; sections. |
| Warnings                   | shall be made, generally in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; or &#8220;Precautions&#8221; section.                                                   |
| Geriatric                  | (10)  Geriatric  use.                                                                                                                                                              |
| Indications                | geriatric population shall be described under the &#8220; Indications and Usage&#8221; section of the labeling, and appropriate                                                    |
| Geriatric                  | The &#8220; Geriatric use&#8221; subsection shall cite any limitations on the                                                                                                      |
| Geriatric                  | Unless otherwise noted, information contained in the &#8220; Geriatric use&#8221; subsection of the labeling shall pertain to                                                      |
| Warnings                   | information shall also be contained in &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; and elsewhere in &#8220;Precautions.&#8221; (ii) Specific statements             |
| Geriatric                  | geriatric indication, shall be contained in the &#8220; Geriatric use&#8221; subsection and shall reflect all information available                                                |
| Geriatric                  | The &#8220; Geriatric use&#8221; subsection shall contain the following statement(s) or                                                                                            |
| Geriatric                  | experience has not identified such differences, the &#8220; Geriatric  use&#8221; subsection shall include the following statement:                                                |
| Geriatric                  | experience has not identified such differences, the &#8220; Geriatric  use&#8221; subsection shall contain the following statement:                                                |
| Geriatric                  | requires specific monitoring or dosage adjustment, the &#8220; Geriatric use&#8221; subsection of the labeling shall contain a                                                     |
| Warnings                   | to more detailed discussions in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; &#8220;Dosage and Administration,&#8221; or other sections of                       |
| Geriatric                  | they shall be described briefly in the &#8220; Geriatric use&#8221; subsection of the labeling and in detail                                                                       |
| Drug                       | The &#8220;Clinical Pharmacology&#8221; section and &#8220; Drug interactions&#8221; subsection of the &#8220;Precautions&#8221; section ordinarily contain                        |
| Geriatric                  | be substantially excreted by the kidney, the &#8220; Geriatric  use&#8221; subsection shall include the statement:                                                                 |
| Geriatric                  | the hazard shall be described in the &#8220; Geriatric use&#8221; subsection of the labeling, or, if appropriate,                                                                  |
| Warnings                   | hazard shall be stated in the &#8220;Contraindications,&#8221; &#8220; Warnings ,&#8221; or &#8220;Precautions&#8221; section of the labeling, and                                 |
| Geriatric                  | the hazard shall be described in the &#8220; Geriatric use&#8221; subsection of the labeling, or, if appropriate,                                                                  |
| Less                       | Less frequent adverse reactions are (list reactions), which occur                                                                                                                  |
| Dependence                 | (h) Drug Abuse and  Dependence .                                                                                                                                                   |
| Substance                  | subsections, as appropriate for the drug: (1) Controlled Substance .                                                                                                               |
| Specific                   | Specific information shall be provided about the following: (1)                                                                                                                    |
| Radiation                  | Radiation dosimetry information shall be stated for both the                                                                                                                       |
| Significant                | Significant animal data necessary for safe and effective use                                                                                                                       |
| Indications                | or dosing regimens not stated in the &#8220; Indications  and Usage&#8221; or &#8220;Dosage and Administration&#8221; section.                                                     |
| Reminder                   | Reminder labeling, other than price lists and catalogs solely                                                                                                                      |
| Reminder                   | Reminder labeling, other than that subject to the requirements                                                                                                                     |
| New                        | New  drugs or new animal drugs.                                                                                                                                                    |
| Drugs                      | Drugs ; expiration of exemptions.                                                                                                                                                  |
| Drugs                      | Drugs ; exemption for radioactive drugs for research use.                                                                                                                          |
| Drugs                      | Drugs ; processing, labeling, or repacking.                                                                                                                                        |
| Such                       | Such person and such operator shall each keep a                                                                                                                                    |
| Medical                    | Medical  gases.                                                                                                                                                                    |
| Food                       | Efficacy Study, A Report to the Commissioner of Food and Drugs from the National Academy of Sciences                                                                               |
| Sciences                   | Food and Drugs from the National Academy of Sciences (1969).&#8221; As the report notes, this review has                                                                           |
| Food                       | (b) The Commissioner of  Food and Drugs concludes that: (1) The failure to                                                                                                         |
| Notice                     | Notice  to manufacturers, packers, and distributors of glandular preparations.                                                                                                     |
| Numerous                   | Numerous preparations of such inert glandular materials were subsequently                                                                                                          |
| Health                     | (c) The Department of  Health and Human Services is of the opinion that                                                                                                            |
| Notice                     | Notice to manufacturers, packers, and distributors of estrogenic hormone                                                                                                           |
| London, England            | Conference on the Standardization of Sex Hormones at London, England , on August 1, 1932.                                                                                          |
| Notice                     | Notice to manufacturers, packers, and distributors of drugs for                                                                                                                    |
| D, and K                   | of provitamin A and the fat-soluble vitamins A, D, and K , and consequently interferes with the utilization of                                                                     |
| Health                     | In view of these facts, the Department of Health and Human Services will regard as misbranded under                                                                                |
| Health                     | against fatalities from this cause, the Department of Health and Human Services will regard as misbranded under                                                                    |
| Tannic                     | Tannic  acid and barium enema preparations.                                                                                                                                        |
| Tannic                     | Tannic acid is capable of causing diminished liver function                                                                                                                        |
| Tannic                     | Tannic acid for rectal use to enhance X-ray visualization                                                                                                                          |
| Food                       | only&#8221; will be regarded by the Commissioner of Food and Drugs as misbranded within the meaning of                                                                             |
| Isoproterenol              | Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human                                                                                        |
| Cardiac                    | Cardiac arrest was noted in several of these cases                                                                                                                                 |
| Food                       | the Respiratory and Anesthetic Drugs Advisory Committee for Food  and Drug Administration, the Commissioner of                                                                     |
| Potassium                  | Potassium  salt preparations intended for oral ingestion by man.                                                                                                                   |
| Sodium                     | Sodium phosphates; package size limitation, warnings, and directions for                                                                                                           |
| Sodium                     | Sodium phosphates oral solution has been marketed in 45-milliliter                                                                                                                 |
| Sodium                     | Sodium phosphates oral solution (adult dose 20 mL to                                                                                                                               |
| Accidental                 | Accidental overdosing and deaths have occurred because the 240-mL                                                                                                                  |
| Children                   | 10 mL (2 teaspoonfuls) in a 24-hour period.&#8221; Children  under 5 years of age: ask a doctor.                                                                                   |
| Ipecac                     | Ipecac syrup; warnings and directions for use for over-the-counter                                                                                                                 |
| United States              | year about 500,000 accidental poisonings occur in the United States and result in approximately 1,500 deaths, of which                                                             |
| Pediatrics                 | the unanimous recommendation of the American Academy of Pediatrics , the American Association of Poison Control Centers,                                                           |
| Food                       | view of the above recommendations, the Commissioner of Food and Drugs has determined that it is in                                                                                 |
| Acetophenetidin            | Acetophenetidin  (phenacetin)-containing preparations; necessary warning statement.                                                                                                |
| Food                       | The Commissioner of  Food and Drugs, in December 1963, appointed an ad                                                                                                             |
| Inquiry                    | 1963, appointed an ad hoc Advisory Committee of Inquiry on Possible Nephrotoxicity Associated With the Abuse of                                                                    |
| Acetophenetidin            | on Possible Nephrotoxicity Associated With the Abuse of Acetophenetidin  (Phenacetin)-Containing Preparations.                                                                     |
| Food                       | the basis of the studies made by the Food and Drug Administration and the report of the                                                                                            |
| Phenindione                | longer than 10 days without consulting your physician.&#8221; Phenindione ; labeling of drug preparations intended for use                                                         |
| Food                       | intended for use by man, the Commissioner of Food and Drugs will regard such preparations as misbranded                                                                            |
| Periodic                   | Periodic blood studies and liver function tests should be                                                                                                                          |
| Magnesium                  | Magnesium  sulfate heptahy- drate; label declaration on drug products.                                                                                                             |
| Magnesium                  | Magnesium sulfate heptahydrate should be listed on the label                                                                                                                       |
| Estradiol                  | Estradiol  labeling.                                                                                                                                                               |
| United States Pharmacopeia | is the same substance formerly recognized in the United States Pharmacopeia under the designation &#8220;Alpha Estradiol.&#8221; The substance should                              |
| Estradiol                  | in The National Formulary under the heading &#8220; Estradiol &#8221; and which is said to be &#8220;17-cis-beta                                                                   |
| Safety                     | Safety closures that prevent access to the drug by                                                                                                                                 |
| Avoid                      | Avoid getting into the eyes or on mucous membranes.&#8221;                                                                                                                         |
| Children                   | following warning: &#8220;Reye's syndrome [subheading in bold type]: Children and teenagers who have or are recovering from                                                        |
| Reye                       | these symptoms could be an early sign of Reye 's syndrome, a rare but serious illness.&#8221; (2)                                                                                  |
| Esophageal                 | Esophageal obstruction and asphyxiation due to orally-administered drug products                                                                                                   |
| Granular                   | Granular dosage forms containing psyllium are not generally recognized                                                                                                             |
| Aluminum                   | Aluminum in large and small volume parenterals used in                                                                                                                             |
| Warnings                   | contain the following warnings under the heading &#8220; Warnings ,&#8221; in accordance with 21 CFR 201.66.                                                                       |
| Severe                     | Severe liver damage may occur if you take [bullet]                                                                                                                                 |
| Severe                     | Severe liver damage may occur if your child takes                                                                                                                                  |
| Severe                     | Severe liver damage may occur if [bullet] adult takes                                                                                                                              |
| New                        | (b)  New  warnings information statement.                                                                                                                                          |
| Such                       | Such labeling may be put into use without advance                                                                                                                                  |
| Uses                       | of the product states, under the heading &#8220; Uses ,&#8221; the phrases listed in this paragraph (c),                                                                           |
| Sunblock                   | but are not limited to the following: &#8220; Sunblock ,&#8221; &#8220;sweatproof,&#8221; and &#8220;waterproof.&#8221; These or similar claims                                    |
| Erythemal                  | in ISO 17166 CIE S 007/E entitled &#8220; Erythemal reference action spectrum and standard erythema dose,&#8221; dated                                                             |
| Switzerland                | Copyright Office, Case Postale 56, CH-1211, Geneva 20, Switzerland , telephone +41-22-749-01-11 or fax +41-22-74-09-47.                                                            |
| Research                   | copy at the Center for Drug Evaluation and Research , 10903 New Hampshire Ave., Bldg.                                                                                              |
| Technology                 | traceable to the National Institute for Standards and Technology ).                                                                                                                |
| Daily                      | Daily solar simulator radiation intensity should be monitored with                                                                                                                 |
| Erythemal                  | in ISO 17166 CIE S 007/E entitled &#8220; Erythemal reference action spectrum and standard erythema dose,&#8221; which                                                             |
| Add                        | Add sufficient water of Part D to the batch                                                                                                                                        |
| Cool                       | Cool  batch to 27 to 32 &#176;C.                                                                                                                                                   |
| Dissolve                   | Dissolve  and dilute to volume with isopropanol.                                                                                                                                   |
| Dissolve                   | Dissolve  and dilute to volume with isopropanol.                                                                                                                                   |
| Dilute                     | Dilute  to volume with isopropanol and mix well.                                                                                                                                   |
| Cool                       | Cool to room temperature (15 to 30 &#176;C) and                                                                                                                                    |
| Determine                  | Determine that each subject is in good general health                                                                                                                              |
| Determine                  | Determine that each subject is not taking topical or                                                                                                                               |
| Determine                  | Determine that each subject has no history of sensitivities                                                                                                                        |
| Woods                      | source of low power UVA, such as a Woods  lamp, is helpful in this process.                                                                                                        |
| Excess                     | Excess hair on the back is acceptable if the                                                                                                                                       |
| Obtain                     | Obtain legally effective written informed consent from all test                                                                                                                    |
| Test                       | (i)  Test  site.                                                                                                                                                                   |
| Test                       | Test sites are locations on each subject's back, between                                                                                                                           |
| Test                       | Test sites should be randomly located in a blinded                                                                                                                                 |
| Test                       | (ii)  Test  subsite.                                                                                                                                                               |
| Test                       | Test subsites are the locations to which UV radiation                                                                                                                              |
| Test                       | Test subsites should be at least 0.5 square centimeters                                                                                                                            |
| Wait                       | Wait at least 15 minutes after applying a sunscreen                                                                                                                                |
| Select                     | Select doses that are a geometric series represented by                                                                                                                            |
| Note                       | Note that the expected SPF equals 1 and 16.3                                                                                                                                       |
| Reject                     | Reject test data for a test subject if erythema                                                                                                                                    |
| Expose                     | Expose test sites to UV doses as described in                                                                                                                                      |
| Mean                       | (i)  Mean transmittance values, (ii) The calculation yields 111 monochromatic                                                                                                      |
| Portable                   | (a)  Portable  cryogenic medical gas containers.                                                                                                                                   |
| Such                       | Such label must meet the requirements of &#167;&#8201;211.94(e)(2) of                                                                                                              |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1969-07-01 | The requirement for inclusion of the ZIP Code shall apply to consumer commodity labels developed or revised after July 1, 1969.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 2001-06-30 | (1) The following categories of prescription drug products are subject to the labeling requirements in paragraph (d) of this section and &#167;&#8201;201.57 in accordance with the implementation schedule in paragraph (c) of this section:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (i) Prescription drug products for which a new drug application (NDA), biologics license application (BLA), or efficacy supplement was approved by the Food and Drug Administration (FDA) between June 30, 2001 and June 30, 2006;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 2006-06-30 | (1) The following categories of prescription drug products are subject to the labeling requirements in paragraph (d) of this section and &#167;&#8201;201.57 in accordance with the implementation schedule in paragraph (c) of this section:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (i) Prescription drug products for which a new drug application (NDA), biologics license application (BLA), or efficacy supplement was approved by the Food and Drug Administration (FDA) between June 30, 2001 and June 30, 2006;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 2006-06-30 | (ii) Prescription drug products for which an NDA, BLA, or efficacy supplement is pending on June 30, 2006; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2006-06-30 | (iii) Prescription drug products for which an NDA, BLA, or efficacy supplement is submitted anytime on or after June 30, 2006.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2006-06-30 | For products described in paragraph (b)(1) of this section, labeling conforming to the requirements in paragraph (d) of this section and &#167;&#8201;201.57 must be submitted according to the following schedule:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (1) For products for which an NDA, BLA, or efficacy supplement is submitted for approval on or after June 30, 2006, proposed conforming labeling must be submitted as part of the application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2006-06-30 | (2) For products for which an NDA, BLA, or efficacy supplement is pending on June 30, 2006, or that has been approved any time from June 30, 2005, up to and including June 30, 2006, a supplement with proposed conforming labeling must be submitted no later than June 30, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2005-06-30 | (2) For products for which an NDA, BLA, or efficacy supplement is pending on June 30, 2006, or that has been approved any time from June 30, 2005, up to and including June 30, 2006, a supplement with proposed conforming labeling must be submitted no later than June 30, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2006-06-30 | (2) For products for which an NDA, BLA, or efficacy supplement is pending on June 30, 2006, or that has been approved any time from June 30, 2005, up to and including June 30, 2006, a supplement with proposed conforming labeling must be submitted no later than June 30, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2009-06-30 | (2) For products for which an NDA, BLA, or efficacy supplement is pending on June 30, 2006, or that has been approved any time from June 30, 2005, up to and including June 30, 2006, a supplement with proposed conforming labeling must be submitted no later than June 30, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2004-06-30 | (3) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2004, up to and including June 29, 2005, a supplement with proposed conforming labeling must be submitted no later than June 30, 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2005-06-29 | (3) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2004, up to and including June 29, 2005, a supplement with proposed conforming labeling must be submitted no later than June 30, 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2010-06-30 | (3) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2004, up to and including June 29, 2005, a supplement with proposed conforming labeling must be submitted no later than June 30, 2010.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2003-06-30 | (4) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2003, up to and including June 29, 2004, a supplement with proposed conforming labeling must be submitted no later than June 30, 2011.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2004-06-29 | (4) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2003, up to and including June 29, 2004, a supplement with proposed conforming labeling must be submitted no later than June 30, 2011.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2011-06-30 | (4) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2003, up to and including June 29, 2004, a supplement with proposed conforming labeling must be submitted no later than June 30, 2011.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2002-06-30 | (5) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2002, up to and including June 29, 2003, a supplement with proposed conforming labeling must be submitted no later than June 30, 2012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2003-06-29 | (5) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2002, up to and including June 29, 2003, a supplement with proposed conforming labeling must be submitted no later than June 30, 2012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2012-06-30 | (5) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2002, up to and including June 29, 2003, a supplement with proposed conforming labeling must be submitted no later than June 30, 2012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2001-06-30 | (6) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2001, up to and including June 29, 2002, a supplement with proposed conforming labeling must be submitted no later than June 30, 2013.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2002-06-29 | (6) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2001, up to and including June 29, 2002, a supplement with proposed conforming labeling must be submitted no later than June 30, 2013.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2013-06-30 | (6) For products for which an NDA, BLA, or efficacy supplement has been approved anytime from June 30, 2001, up to and including June 29, 2002, a supplement with proposed conforming labeling must be submitted no later than June 30, 2013.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2007-06-30 | (6) The requirement in &#167;&#8201;201.80(f)(2) to reprint any FDA-approved patient labeling at the end of prescription drug labeling or accompany the prescription drug labeling must be implemented no later than June 30, 2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2007-06-30 | The requirements in this section apply only to prescription drug products described in &#167;&#8201;201.56(b)(1) and must be implemented according to the schedule specified in &#167;&#8201;201.56(c), except for the requirement in paragraph (c)(18) of this section to reprint any FDA-approved patient labeling at the end of prescription drug labeling or accompany the prescription drug labeling, which must be implemented no later than June 30, 2007.                                                                                                                                                                                                                                                                          |
| 2018-01-02 | (8) The information required by paragraph (a) of this section, not including the information required under paragraph (a)(4) of this section, must be limited in length to an amount that, if printed in 2 columns on a standard sized piece of typing paper (81/2 by 11 inches), single spaced, in 8 point type with 1/2-inch margins on all sides and between columns, would fit on one-half of the page.                                                                                                                                                                                                                                                                                                                                |
| 2018-11-02 | (k) Examples:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (1) A declaration of 11/2 pounds weight shall be expressed as &#8220;Net wt.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2018-11-02 | 24 oz (11/2 lb)&#8221; or &#8220;Net wt.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 2018-03-04 | Examples of linear measure are &#8220;86 inches (2 yd 1 ft 2 in),&#8221; &#8220;90 inches (21/2 yd),&#8221; &#8220;30 inches (2.5 ft),&#8221; &#8220; 3/4 inch by 36 in (1 yd),&#8221; etc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2018-12-01 | The declaration in terms of the largest whole units shall be in parentheses following the declaration in terms of square inches and any remainder shall be in terms of square inches or common or decimal fractions of the square foot or square yard; for example, &#8220;158 sq inches (1 sq ft 14 sq in).&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (o) Nothing in this section shall prohibit supplemental statements at locations other than the principal display panel(s) describing in nondeceptive terms the net quantity of contents, provided that such supplemental statements of net quantity of contents shall not include any term qualifying a unit of weight, measure, or count that tends to exaggerate the amount of the drug contained in the package; for example, &#8220;giant pint&#8221; and &#8220;full quart.&#8221; Dual or combination declarations of net quantity of contents as provided for in paragraphs (a) and (i) of this section are not regarded as supplemental net quantity statements and shall be located on the principal display panel. |
| 1997-04-22 | (i) Any product subject to this paragraph that contains sodium bicarbonate, sodium phosphate, or sodium biphosphate as an active ingredient for oral ingestion and that is not labeled as required by this paragraph and that is initially introduced or initially delivered for introduction into interstate commerce after April 22, 1997, is misbranded under sections 201(n) and 502 (a) and (f) of the Federal Food, Drug, and Cosmetic Act (the act).                                                                                                                                                                                                                                                                                |
| 2004-04-23 | (1) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2004-04-23 | (2) Septemeber 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2005-11-29 | Any product subject to this paragraph that contains dibasic sodium phosphate and/or monobasic sodium phosphate as an active ingredient intended for rectal administration and that is not labeled as required by this paragraph and that is initially introduced or initially delivered for introduction into interstate commerce after November 29, 2005, is misbranded under sections 201(n) and 502(a) and (f) of the act.                                                                                                                                                                                                                                                                                                              |
| 2004-04-23 | (1) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2005-09-24 | (2) September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2004-04-23 | (2) September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2004-04-23 | (1) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2018-09-24 | (2) September 24.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 2004-04-23 | 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 2004-04-23 | (1) As of the date of approval of the application for any single entity and combination products subject to drug marketing applications approved on or after April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2005-09-24 | (2) September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 2004-04-23 | (2) September 24, 2005, for all OTC drug products subject to any OTC drug monograph, not yet the subject of any OTC drug monograph, or subject to drug marketing applications approved before April 23, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 1972-05-15 | (d) For new drugs and antibiotics, supplements to provide for revised labeling in accord with paragraph (c) of this section shall be submitted under the provisions of &#167;&#8201;314.70 and &#167;&#8201;514.8 of this chapter within 90 days after publication of the implementation notice in the Federal Register or by May 15, 1972, for those drugs for which notices have been published and such labeling shall be put into use as soon as possible but not later than the end of the time period allowed for submitting supplements to provide for revised labeling.                                                                                                                                                            |
| 1941-12-04 | (a) Under date of December 4, 1941, in a notice to manufacturers of glandular preparations, the Food and Drug Administration expressed the opinion that preparations of inert glandular materials intended for medicinal use should, in view of the requirement of section 201(n) of the Federal Food, Drug, and Cosmetic Act (52 Stat.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 1932-08-01 | The international unit of the estrus-producing hormone was established by the International Conference on the Standardization of Sex Hormones at London, England, on August 1, 1932.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1998-06-22 | (c) After June 22, 1998, for package size limitation and September 18, 1998, for labeling in accord with paragraph (b) of this section, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce, or any such drug product that is repackaged or relabeled after these dates regardless of the date the product was manufactured, initially introduced, or initially delivered for introduction into interstate commerce, that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                              |
| 1998-09-18 | (c) After June 22, 1998, for package size limitation and September 18, 1998, for labeling in accord with paragraph (b) of this section, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce, or any such drug product that is repackaged or relabeled after these dates regardless of the date the product was manufactured, initially introduced, or initially delivered for introduction into interstate commerce, that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                              |
| 1963-12-01 | The Commissioner of Food and Drugs, in December 1963, appointed an ad hoc Advisory Committee of Inquiry on Possible Nephrotoxicity Associated With the Abuse of Acetophenetidin (Phenacetin)-Containing Preparations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1964-04-23 | This committee, composed of scientists in the fields of pharmacology and medicine, on April 23, 1964, submitted its findings and conclusions in the matter and recommended that all acetophenetidin (phenacetin)-containing preparations bear a warning as provided in section 502(f)(2) of the Federal Food, Drug, and Cosmetic Act.                                                                                                                                                                                                                                                                                                                                                                                                      |
| 1961-11-25 | Use of the drug should be discontinued if leukopenia occurs or if evidence of hypersensitivity, such as dermatitis or fever, appears.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (b) Regulatory action may be initiated with respect to preparations of phenindione intended for use by man found within the jurisdiction of the act on or after November 25, 1961, unless such preparations are labeled in accordance with paragraph (a) of this section.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 2018-11-04 | (c) Aspirin tablets sold as such and containing no other active ingredients, except tablets which cannot be readily subdivided into a child's dose because of their coating or size, should always bear dosage directions for each age group down to 3 years of age, with a statement such as &#8220;For children under 3 years of age, consult your physician.&#8221; It is recommended that:                                                                                                                                                                                                                                                                                                                                             |
|            |               (1) Aspirin tablets especially made for pediatric use be produced only in 11/4-grain size to reduce the hazard of errors in dosage;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (2) By June 1, 1967, manufacturers and distributors of 11/4-grain size aspirin tablets discontinue the distribution of such tablets in retail containers containing more than 36 tablets, to reduce the hazard of accidental poisoning;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (3) The flavoring of 5-grain aspirin tablets or other &#8220;adult aspirin tablets&#8221; be discontinued; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (4) Labeling giving undue emphasis to the pleasant flavor of flavored aspirin tablets be discontinued.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1967-06-01 | (c) Aspirin tablets sold as such and containing no other active ingredients, except tablets which cannot be readily subdivided into a child's dose because of their coating or size, should always bear dosage directions for each age group down to 3 years of age, with a statement such as &#8220;For children under 3 years of age, consult your physician.&#8221; It is recommended that:                                                                                                                                                                                                                                                                                                                                             |
|            |               (1) Aspirin tablets especially made for pediatric use be produced only in 11/4-grain size to reduce the hazard of errors in dosage;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (2) By June 1, 1967, manufacturers and distributors of 11/4-grain size aspirin tablets discontinue the distribution of such tablets in retail containers containing more than 36 tablets, to reduce the hazard of accidental poisoning;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (3) The flavoring of 5-grain aspirin tablets or other &#8220;adult aspirin tablets&#8221; be discontinued; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (4) Labeling giving undue emphasis to the pleasant flavor of flavored aspirin tablets be discontinued.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 2004-10-18 | (i) Compliance by October 18, 2004, for OTC drug products containing aspirin and nonaspirin salicylates as an active ingredient and marketed under a new drug application or abbreviated new drug application.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2004-04-19 | (ii) Compliance by April 19, 2004, for OTC antidiarrheal and overindulgence drug products that contain bismuth subsalicylate as an active ingredient and have annual sales greater than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 2005-04-18 | (iii) Compliance by April 18, 2005, for OTC antidiarrheal and overindulgence drug products that contain bismuth subsalicylate as an active ingredient and have annual sales less than $25,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2018-01-04 | Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.                                                                                                                                                                                                                                                                                                              |
| 2018-01-04 | (a) Reports in the medical literature and data accumulated by the Food and Drug Administration indicate that esophageal obstruction and asphyxiation have been associated with the ingestion of water-soluble gums, hydrophilic gums, and hydrophilic mucilloids including, but not limited to, agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil, tragacanth, and xanthan gum.                                                                                                                                                                      |
| 1994-02-28 | (c) After February 28, 1994, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce, or any such drug product that is repackaged or relabeled after this date regardless of the date the product was manufactured, initially introduced, or initially delivered for introduction into interstate commerce, that is not in compliance with this section is subject to regulatory action.                                                                                                                                                                                                                                                                                           |
| 2004-07-26 | The aluminum content must be stated as follows: &#8220;Contains no more than __ &#181;g/L of aluminum.&#8221; The immediate container label of all SVP's and PBP's that are lyophilized powders used in the preparation of TPN solutions must contain the following statement: &#8220;When reconstituted in accordance with the package insert instructions, the concentration of aluminum will be no more than __ &#181;g/L.&#8221; This maximum level of aluminum must be stated as the highest of:                                                                                                                                                                                                                                      |
|            |               (1) The highest level for the batches produced during the last 3 years;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (2) The highest level for the latest five batches, or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|            |               (3) The maximum historical level, but only until completion of production of the first five batches after July 26, 2004.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2008-06-19 | (e) Any drug product subject to this section that is not labeled as required and that is initially introduced or initially delivered for introduction into interstate commerce after June 19, 2008, is misbranded under section 502 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 352), is a new drug under section 505 of the act (21 U.S.C. 355), and is subject to regulatory action.                                                                                                                                                                                                                                                                                                                                |
| 2010-04-29 | The labeling of any drug product subject to this section that is initially introduced or initially delivered for introduction into interstate commerce before or on April 29, 2010, must bear on its PDP, as defined in &#167;&#8201;201.60, the statement &#8220;See new warnings information&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2018-12-01 | To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: [Bullet] limit time in the sun, especially from 10 a.m.-2 p.m. [bullet] wear long-sleeved shirts, pants, hats, and sunglasses&#8221;.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 1999-12-15 | (A) Calculate the erythema action spectrum weighting factor (Vi) at each wavelength &#955;:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) Vi (&#955;) = 1.0 (250 &lt;&#955; &#8804;298 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) Vi (&#955;) = 100.094* (298                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |                 &#8722;&#955;) (298 &lt;&#955; &#8804;328 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (3) Vi (&#955;) = 100.015* (140                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |                 &#8722;&#955;) (328 &lt;&#955; &#8804;400 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (B) Calculate the erythema-effective UV dose (E) delivered by a solar simulator as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (C) The emission spectrum must be determined using a handheld radiometer with a response weighted to match the spectrum in ISO 17166 CIE S 007/E entitled &#8220;Erythemal reference action spectrum and standard erythema dose,&#8221; dated 1999 (First edition, 1999-12-15; corrected and reprinted 2000-11-15), which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51.                                                                                                                                                                                                                                                                                                                 |
| 2000-11-15 | (A) Calculate the erythema action spectrum weighting factor (Vi) at each wavelength &#955;:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) Vi (&#955;) = 1.0 (250 &lt;&#955; &#8804;298 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (2) Vi (&#955;) = 100.094* (298                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |                 &#8722;&#955;) (298 &lt;&#955; &#8804;328 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (3) Vi (&#955;) = 100.015* (140                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |                 &#8722;&#955;) (328 &lt;&#955; &#8804;400 nm)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (B) Calculate the erythema-effective UV dose (E) delivered by a solar simulator as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (C) The emission spectrum must be determined using a handheld radiometer with a response weighted to match the spectrum in ISO 17166 CIE S 007/E entitled &#8220;Erythemal reference action spectrum and standard erythema dose,&#8221; dated 1999 (First edition, 1999-12-15; corrected and reprinted 2000-11-15), which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51.                                                                                                                                                                                                                                                                                                                 |


